Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
COMPOSITIONS AND METHODS FOR DETECTING
GASTROINTESTINAL PATHOGENS
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit under priority of United States
Provisional
Application No. 63/226,079, filed July 27, 2021, the disclosure of which is
hereby
incorporated by reference in its entirety.
INTRODUCTION AND SUMMARY
[0002] Bacterial gastroenteritis is inflammation of the stomach and intestines
that results in
acute diarrhea (3 or more episodes per day) lasting less than 14 days and may
also include
symptoms such as nausea, vomiting, and abdominal cramping. See Thielman and
Guerrant,
The New England Journal of Medicine, 350:38-47, 2004. In the United States, it
is estimated that
there are more than 200 million cases of diarrheal illness per year, resulting
in 73 million
physician consultations, 1.8 million hospitalizations, and up to 6,000 deaths.
See Guerrant et
al., Clinical Infectious Diseases, 32:331-350, 2001. According to the Centers
for Disease Control
Food Net data (data compilation from 10 state health departments), in 2010,
the number of
reported infections and incidence per 100,000 population included the
following: Salmonella
(8256; 17.6), Campylobacter (6365; 13.6), and Shigella (1780; 3.8). See
Centers for Disease
Control and Prevention, "Vital Signs: Incidence and Trends of Infection with
Pathogens
Transmitted Commonly Through Food ¨ Foodborne Diseases Active Surveillance
Network,
U.S. Sites, 1996-2010," MAI-1FR 60(22):749-755, 2011. These three bacteria,
along with
Shigatoxigenic Escherichia coli (STEC), are common causes of bacterial
gastroenteritis. The
populations most at risk due to bacterial gastroenteritis infection are
children (5), the
elderly, and the immunocompromised. Infection, however, can occur in all age
groups. The
mode of infection is via the fecal-oral route typically from ingesting
contaminated food or
water or as a result of poor hygiene (hand-washing).
[0003] Salmonella are gram-negative, aerobic, rod-shaped bacilli. There are
two species of
Salmonella, including enterica and bongori. Salmonella enterica is further
divided into six subspecies
with only a fraction of Salmonella enterica subspecies I being responsible for
human illness. See
Sabbagh et al., FEMS Microbiol Lett 305:1-13, 2010. Salmonella serotypes
Typhimurium,
1
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
Enteritidis, and Newport account for about half of the culture-confirmed
Salmonella isolates
in the US. Salmonella serotype Typhi, the strain that causes typhoid fever, is
uncommon in
the US, while Salmonella serotypes Mississippi and Javiana have been
increasingly identified as
a source of illness. See Centers for Disease Control and Prevention, "Summary
of Notifiable
Diseases¨United States, 2008," MiVIVR 57(54):15-16, 2008.
[0004] Campylobacter are curved, motile, microaerophilic, gram-negative rods.
They exhibit
rapid, darting motility in a corkscrew fashion using one or two flagella and
also have a
lipopolysaccharide endotoxin. Two species of Campylobacter, C. .guni and C.
co/i, are
responsible for the vast majority of human infections. See Klena et al.,
Journal of Clinical
Microbiology, 42:5549-5557, 2004; Poly and Guerry, Current Opinion in
Gastroenterology 24:27-31,
2008; Granato et al., Journal of Clinical Microbiology, 48:4022-4027, 2010.
[0005] E. coli are gram-negative, rod-shaped bacteria that are commonly found
in the lower
intestines of warm-blooded organisms. Most strains of E. co/i are non-
pathogenic and are
part of the normal gut flora. However, some strains, such as STEC, can cause
life-
threatening infections in humans. There are two main types of Shiga toxin
produced by
STEC, Shiga toxin type 1 and Shiga toxin type 2, which are carried on two
different genes,
six/ and stx2, respectively. Some strains of STEC contain the six/ gene while
other strains
contain the stx2 gene. There are also certain strains of STEC that contain
both the six/ and
stx2 genes.
[0006] Shigella are gram-negative, aerobic, rod-shaped bacteria that are
closely related to E.
co/i. See Liu et al., FEMS Microbiol. Rev. 32:627-653, 2008. There are four
species of Shigella,
all of which can cause disease in humans and include S. sonnei (subgroup D),
S. flexneri
(subgroup B), S. boydii (subgroup B), and S. clysenteriae (subgroup A).
According to the 2006
Shigella annual summary published by the CDC, S. sonnei is the most prevalent
cause of
infections at 76%, followed by S. flexneri (14%), S. boydii (1.1%), and S.
clysenteriae (0.5%). See
Centers for Disease Control and Prevention, "Shigella Surveillance: Annual
Summary, 2006,"
Atlanta, GA: US Department of Health and Human Services, November 2008.
[0007] There is a need to efficiently and sensitively detect the presence of
Salmonella, Shigella,
Campylobacter, and STEC in samples, including biological specimens to provide
diagnostic
2
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
and prognostic information to physicians treating patients suffering from, or
suspected of
suffering from, bacterial gastroenteritis or related disorders.
[0008] Accordingly, provided herein is a set of oligonucleotides for
determining the presence
or absence of at least one enteric pathogen, said set of oligonucleotides
comprising at least
one of (a)-(e):
(a) a Salmonella-specific amplification oligomer set comprising first and
second oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of: (i) SEQ ID NO:12 and SEQ ID NO:14; SEQ ID NO:21
and
SEQ ID NO:47; SEQ ID NO:38 and SEQ ID NO:36; (iv) SEQ ID NO:35 and SEQ
ID NO:40; (v) SEQ ID NO:12 and SEQ ID NO:28; (vi) SEQ ID NO:42 and SEQ ID
NO:31; or (vii) SEQ ID NO:41 and SEQ ID NO:27;
(b) a C..guni-specific amplification oligomer set comprising first and
second oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of: (i) SEQ ID NO:11 and SEQ ID NO:19;
(c) a C. co/i-specific amplification oligomer set comprising first and
second oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of: (i) SEQ ID NO:8 and SEQ ID NO:10;
(d) a Shigella-specific amplification oligomer set comprising first and
second oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of: (i) SEQ ID NO:15 and SEQ ID NO:17; SEQ ID NO:34
and
SEQ ID NO:22; or (iii) SEQ ID NO:32 and SEQ ID NO:33; and
(e) a Shigatoxigenic E. co/i (STEC)-specific amplification oligomer set
comprising first
and second oligomers respectively comprising target-hybridizing sequences
substantially
corresponding to the nucleotide sequences of: (i) SEQ ID NO:20 and SEQ ID
NO:3; (ii)
SEQ ID NO:49 and SEQ ID NO:3; or (iii) SEQ ID NO:4 and SEQ ID NO:7.
[0009] In some embodiments, the set of oligonucleotides comprises the
Salmonella-specific
amplification oligomer set. In some embodiments, the Salmonella-specific
amplification
oligomer set comprises first and second oligomers respectively comprising
target-hybridizing
sequences substantially corresponding to the nucleotide sequences of SEQ ID
NO:21 and
3
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
SEQ ID NO:47. In some embodiments, the Salmonella-specific amplification
oligomer set
comprises first and second oligomers respectively comprising target-
hybridizing sequences
substantially corresponding to the nucleotide sequences of SEQ ID NO:38 and
SEQ ID
NO:36. In some embodiments, the Salmonella-specific amplification oligomer set
comprises
first and second oligomers respectively comprising target-hybridizing
sequences substantially
corresponding to the nucleotide sequences of SEQ ID NO:35 and SEQ ID NO:40. In
some
embodiments, the Salmonella-specific amplification oligomer set comprises
first and second
oligomers respectively comprising target-hybridizing sequences substantially
corresponding
to the nucleotide sequences of SEQ ID NO:12 and SEQ ID NO:28. In some
embodiments,
the Salmonella-specific amplification oligomer set comprises first and second
oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of SEQ ID NO:42 and SEQ ID NO:31. In some embodiments,
the
Salmonella-specific amplification oligomer set comprises first and second
oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of SEQ ID NO:41 and SEQ ID NO:27.
[0010] In some embodiments, the set of oligonucleotides comprises the C.
jejuni-specific
amplification oligomer set.
[0011] In some embodiments, the set of oligonucleotides comprises the C. coll-
specific
amplification oligomer set.
[0012] In some embodiments, the set of oligonucleotides comprises the Shigella-
specific
amplification oligomer set. In some embodiments, the Shigella-specific
amplification
oligomer set comprises first and second oligomers respectively comprising
target-hybridizing
sequences substantially corresponding to the nucleotide sequences of SEQ ID
NO:15 and
SEQ ID NO:17. In some embodiments, the Shigella-specific amplification
oligomer set
comprises first and second oligomers respectively comprising target-
hybridizing sequences
substantially corresponding to the nucleotide sequences of SEQ ID NO:34 and
SEQ ID
NO:22. In some embodiments, the Shigella-specific amplification oligomer set
comprises first
and second oligomers respectively comprising target-hybridizing sequences
substantially
corresponding to the nucleotide sequences of SEQ ID NO:32 and SEQ ID NO:33.
4
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[0013] In some embodiments, the set of oligonucleotides comprises the STEC-
specific
amplification oligomer set.
[0014] In some embodiments, the set of oligonucleotides comprises at least two
of the
Salmonella-specific amplification oligomer set, the C..guni-specific
amplification oligomer set,
the C. co/i-specific amplification oligomer set, the Shigella-specific
amplification oligomer set,
and the STEC-specific amplification oligomer set.
[0015] In some embodiments, the set of oligonucleotides comprises at least
three of the
Salmonella-specific amplification oligomer set, the C. jg.uni-specific
amplification oligomer set,
the C. co/i-specific amplification oligomer set, the Shigella-specific
amplification oligomer set,
and the STEC-specific amplification oligomer set.
[0016] In some embodiments, the set of oligonucleotides comprises at least
four of the
Salmonella-specific amplification oligomer set, the C. jg.uni-specific
amplification oligomer set,
the C. co/i-specific amplification oligomer set, the Shigella-specific
amplification oligomer set,
and the STEC-specific amplification oligomer set.
[0017] In some embodiments, the set of oligonucleotides comprises the
Salmonella-specific
amplification oligomer set, the C. jg.uni-specific amplification oligomer set,
the C. co/i-specific
amplification oligomer set, the Shigeila-specific amplification oligomer set,
and the STEC-
specific amplification oligomer set.
[0018] In some embodiments, the Salmonella-specific amplification oligomer set
comprises
first and second oligomers respectively comprising target-hybridizing
sequences substantially
corresponding to the nucleotide sequences of SEQ ID NO:12 and SEQ ID NO:14;
the C..guni-specific amplification oligomer set comprises first and second
oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of SEQ ID NO:11 and SEQ ID NO:19;
the C. co/i-specific amplification oligomer set comprises first and second
oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of SEQ ID NO:8 and SEQ ID NO:10;
the Shigella-specific amplification oligomer set comprises first and second
oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
nucleotide sequences of SEQ ID NO:15 and SEQ ID NO:17; and
the STEC-specific amplification oligomer set comprises first and second
oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of (i) SEQ ID NO:20 and SEQ ID NO:3; and (ii) SEQ ID NO:4
and
SEQ ID NO:7.
[0019] In some embodiments, the set of oligonucleotides further comprises
a Salmonella detection probe, comprising a target-hybridizing sequence
substantially
corresponding to the nucleotide sequence of:
SEQ ID NO:13 if the Salmonella-specific amplification oligomer set comprises
first and
second oligomers respectively comprising target-hybridizing sequences
substantially
corresponding to the nucleotide sequences of SEQ ID NO:12 and SEQ ID NO:14;
SEQ ID NO:13 if the Salmonella-specific amplification oligomer set comprises
first and
second oligomers respectively comprising target-hybridizing sequences
substantially
corresponding to the nucleotide sequences of SEQ ID NO:12 and SEQ ID NO:28;
SEQ ID NO:45 if the Salmonella-specific amplification oligomer set comprises
first and
second oligomers respectively comprising target-hybridizing sequences
substantially
corresponding to the nucleotide sequences of SEQ ID NO:21 and SEQ ID NO:47;
SEQ ID NO:44, SEQ ID NO:26, or SEQ ID NO:25 if the Salmonella-specific
amplification
oligomer set comprises first and second oligomers respectively comprising
target-hybridizing
sequences substantially corresponding to the nucleotide sequences of SEQ ID
NO:38 and
SEQ ID NO:36;
SEQ ID NO:30 if the Salmonella-specific amplification oligomer set comprises
first and
second oligomers respectively comprising target-hybridizing sequences
substantially
corresponding to the nucleotide sequences of SEQ ID NO:35 and SEQ ID NO:40;
SEQ ID NO:23 if the Salmonella-specific amplification oligomer set comprises
first and
second oligomers respectively comprising target-hybridizing sequences
substantially
corresponding to the nucleotide sequences of SEQ ID NO:42 and SEQ ID NO:31; or
SEQ ID NO:43 if the Salmonella-specific amplification oligomer set comprises
first and
6
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
second oligomers respectively comprising target-hybridizing sequences
substantially
corresponding to the nucleotide sequences of SEQ ID NO:41 and SEQ ID NO:27.
[0020] In some embodiments, in SEQ ID NO:23, one or more, or each of
nucleotides 2, 5,
7, and 14 is 5-methylcytosine. In some embodiments, in SEQ ID NO:25, one or
more, or
each of nucleotides 7,9, 13, and 15 is 5-methylcytosine. In some embodiments,
in SEQ ID
NO:26, one or more, or each of nucleotides 9, 18, and 23 is 5-methylcytosine.
In some
embodiments, in SEQ ID NO:27, one or more, or each of nucleotides 6, 10, and
18 is 5-
methylcytosine. In some embodiments, in SEQ ID NO:30, one or more, or each of
nucleotides 2, 4, 18, 19, and 20 is 5-methylcytosine. In some embodiments, in
SEQ ID
NO:43, one or more, or each of nucleotides 2,9, 12, 16, 17, 22, 23, and 26 is
5-
methylcytosine. In some embodiments, in SEQ ID NO:44, one or more, or each of
nucleotides 7, 9, 13, and 15 is 5-methylcytosine. In some embodiments, in SEQ
ID NO:45,
one or more, or each of nucleotides 3, 6, 8, and 17 is 5-methylcytosine.
[0021] In some embodiments, the set of oligonucleotides further comprises a C.
j gitni
detection probe, the C. .guni detection probe comprising a target-hybridizing
sequence
substantially corresponding to the nucleotide sequence of SEQ ID NO:18.
[0022] In some embodiments, in SEQ ID NO:18, one or more of nucleotides 7, 12,
and 25,
or each of nucleotides 7 and 12, or each of nucleotides 7, 12, and 25 is 5-
methylcytosine.
[0023] In some embodiments, the set of oligonucleotides further comprises a C.
co/i
detection probe, the C. co/i detection probe comprising a target-hybridizing
sequence
substantially corresponding to the nucleotide sequence of SEQ ID NO:9, SEQ ID
NO:37,
or SEQ ID NO:39.
[0024] In some embodiments, in SEQ ID NO:9, one or more, or each of
nucleotides 2, 6,
13, 16, 23, 26, 28, and 29 is 5-methylcytosine. In some embodiments, in SEQ ID
NO:37,
one or more, or each of nucleotides 17, 22, 23, and 27 is 5-methylcytosine. In
some
embodiments, in SEQ ID NO:39, one or more, or each of nucleotides 2,9, 12, 19,
22, 24,
and 25 is 5-methylcytosine.
[0025] In some embodiments, the set of oligonucleotides further comprises
a Shigella detection probe, the Shigella detection probe comprising a target-
hybridizing
7
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
sequence substantially corresponding to the nucleotide sequence of
SEQ ID NO:16 if the Shigella-specific amplification oligomer set comprises
first and
second oligomers respectively comprising target-hybridizing sequences
substantially
corresponding to the nucleotide sequences of SEQ ID NO:15 and SEQ ID NO:17;
SEQ ID NO:46 or SEQ ID NO:29 if the Shigella-specific amplification oligomer
set
comprises first and second oligomers respectively comprising target-
hybridizing sequences
substantially corresponding to the nucleotide sequences of SEQ ID NO:34 and
SEQ ID
NO:22; or
SEQ ID NO:24 if the Shigella-specific amplification oligomer set comprises
first and
second oligomers respectively comprising target-hybridizing sequences
substantially
corresponding to the nucleotide sequences of SEQ ID NO:32 and SEQ ID NO:33.
[0026] In some embodiments, in SEQ ID NO:46, each of nucleotides 5, 11, and 12
is 5-
methylcytosine.
[0027] In some embodiments, the set of oligonucleotides further comprises
a STEC detection probe, the STEC detection probe comprising a target-
hybridizing
sequence substantially corresponding to the nucleotide sequence of
SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:48 if the STEC-specific amplification
oligomer set comprises first and second oligomers respectively comprising
target-hybridizing
sequences substantially corresponding to the nucleotide sequences of SEQ ID
NO:20 and
SEQ ID NO:3;
SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:48 if the STEC-specific amplification
oligomer set comprises first and second oligomers respectively comprising
target-hybridizing
sequences substantially corresponding to the nucleotide sequences of SEQ ID
NO:49 and
SEQ ID NO:3; or
SEQ ID NO:5 or SEQ ID NO:6 if the STEC-specific amplification oligomer set
comprises first and second oligomers respectively comprising target-
hybridizing sequences
substantially corresponding to the nucleotide sequences of SEQ ID NO:4 and SEQ
ID
NO:7.
8
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[0028] In some embodiments, in SEQ ID NO:1, one or more, or each of
nucleotides 6,7, 9,
14, 17, and 24 is 5-methylcytosine. In some embodiments, in SEQ ID NO:2, one
or more,
or each of nucleotides 5, 8, 11, 13, 18, and 21 is 5-methylcytosine. In some
embodiments, in
SEQ ID NO:6, one or more, or each of nucleotides 3,7, 8, 15, 20, 24, and 27 is
5-
methylcytosine. In some embodiments, in SEQ ID NO:15, one or more, or each of
nucleotides 7 and 15 is 5-methylcytosine. In some embodiments, in SEQ ID
NO:19, one or
more, or each of nucleotides 1, 2, 7, 14, 15, 19, and 20 is 5-methylcytosine.
In some
embodiments, in SEQ ID NO:21, one or more, or each of nucleotides 13, 17, and
24 is 5-
methylcytosine. In some embodiments, in SEQ ID NO:28, one or more, or each of
nucleotides 2, 4, 12, 14, 15, and 17 is 5-methylcytosine. In some embodiments,
in SEQ ID
NO:31, one or more, or each of nucleotides 6, 7, 8, 13, 23, 24, and 26 is 5-
methylcytosine. In
some embodiments, in SEQ ID NO:32, one or more, or each of nucleotides 5, 11,
12, and
15 is 5-methylcytosine. In some embodiments, in SEQ ID NO:36, one or more, or
each of
nucleotides 2, 3, 4, 16, 18, 19, and 22 is 5-methylcytosine. In some
embodiments, in SEQ ID
NO:38, one or more, or each of nucleotides 4, 6, 7, and 8 is 5-methylcytosine.
In some
embodiments, in SEQ ID NO:40, one or more, or each of nucleotides 4, 13, 18,
and 22 is 5-
methylcytosine. In some embodiments, in SEQ ID NO:47, one or more, or each of
nucleotides 11, 16, and 17 is 5-methylcytosine. In some embodiments, in SEQ ID
NO:7,
one or more, or each of nucleotides 3,4, 18, and 19 is 5-methylcytosine. In
some
embodiments, in SEQ ID NO:12, one or more, or each of nucleotides 4, 11, 12,
and 16 is 5-
methylcytosine. In some embodiments, in SEQ ID NO:22, each of nucleotides 5
and 16 is
5-methylcytosine.
[0029] In some embodiments, one or more, or each, of the detection probes
comprises a
fluorescent dye compound. In some embodiments, each of the detection probes
further
comprises a non-fluorescent quenching dye compound.
[0030] Also provided herein is an oligonucleotide for determining the presence
or absence
of at least one enteric pathogen, wherein the oligonucleotide comprises the
sequence of any
one of:
SEQ ID NO:15, wherein each of nucleotides 7 and 15 is 5-methylcytosine;
9
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
SEQ ID NO:16;
SEQ ID NO:19, wherein each of nucleotides 1, 2, 7, 14, 15, 19, and 20 is 5-
methylcytosine;
SEQ ID NO:21, wherein each of nucleotides 13, 17, and 24 is 5-methylcytosine;
SEQ ID NO:23, wherein each of nucleotides 2, 5, 7, and 14 is 5-methylcytosine;
SEQ ID NO:25, wherein each of nucleotides 7,9, 13, and 15 is 5-methylcytosine;
SEQ ID NO:26, wherein each of nucleotides 9, 18, and 23 is 5-methylcytosine;
SEQ ID NO:27, wherein each of nucleotides 6, 10, and 18 comprises 5-
methylcytosine;
SEQ ID NO:28, wherein each of nucleotides 2, 4, 12, 14, 15, and 17 is 5-
methylcytosine;
SEQ ID NO:30, wherein each of nucleotides 2, 4, 18, 19, and 20 is 5-
methylcytosine;
SEQ ID NO:31, wherein each of nucleotides 6, 7, 8, 13, 23, 24, and 26 is 5-
methylcytosine;
SEQ ID NO:32, wherein each of nucleotides 5, 11, 12, and 15 is 5-
methylcytosine;
SEQ ID NO:36, wherein each of nucleotides 2, 3, 4, 16, 18, 19, and 22 is 5-
methylcytosine;
SEQ ID NO:38, wherein each of nucleotides 4, 6, 7, and 8 is 5-methylcytosine;
SEQ ID NO:39, wherein each of nucleotides 2, 9, 12, 19, 22, 24, and 25 is 5-
methylcytosine;
SEQ ID NO:40, wherein each of nucleotides 4, 13, 18, and 22 is 5-
methylcytosine;
SEQ ID NO:42;
SEQ ID NO:43, wherein each of nucleotides 2,9, 12, 16, 17, 22, 23, and 26 is 5-
methylcytosine;
SEQ ID NO:44, wherein each of nucleotides 7,9, 13, and 15 is 5-methylcytosine;
SEQ ID NO:45, wherein each of nucleotides 3, 6, 8, and 17 is 5-methylcytosine;
SEQ ID NO:47, wherein each of nucleotides 11, 16, and 17 is 5-methylcytosine;
SEQ ID NO:1, wherein each of nucleotides 6, 7, 9, 14, 17, and 24 is 5-
methylcytosine;
SEQ ID NO:2, wherein each of nucleotides 5, 8, 11, 13, 18, and 21 is 5-
methylcytosine;
SEQ ID NO:6, wherein each of nucleotides 3, 7, 8, 15, 20, 24, and 27 is 5-
methylcytosine;
SEQ ID NO:7, wherein each of nucleotides 3, 4, 18, and 19 is 5-methylcytosine;
SEQ ID NO:9, wherein each of nucleotides 2, 6, 13, 16, 23, 26, 28, and 29 is 5-
methylcytosine;
SEQ ID NO:12, wherein each of nucleotides 4, 11, 12, and 16 is 5-
methylcytosine;
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
SEQ ID NO:18, wherein each of nucleotides 7 and 12 or each of nucleotides 7,
12, and 25
is 5-methylcytosine;
SEQ ID NO:22, wherein each of nucleotides 5 and 16 is 5-methylcytosine;
SEQ ID NO:37, wherein each of nucleotides 17, 22, 23, and 27 is 5-
methylcytosine; and
SEQ ID NO:46, wherein each of nucleotides 5, 11, and 12 is 5-methylcytosine.
[0031] In some embodiments, the oligonucleotide comprises the sequence of any
one of:
SEQ ID NO:15, wherein each of nucleotides 7 and 15 is 5-methylcytosine;
SEQ ID NO:16;
SEQ ID NO:19, wherein each of nucleotides 1, 2, 7, 14, 15, 19, and 20 is 5-
methylcytosine;
SEQ ID NO:21, wherein each of nucleotides 13, 17, and 24 is 5-methylcytosine;
SEQ ID NO:23, wherein each of nucleotides 2, 5, 7, and 14 is 5-methylcytosine;
SEQ ID NO:25, wherein each of nucleotides 7,9, 13, and 15 is 5-methylcytosine;
SEQ ID NO:26, wherein each of nucleotides 9, 18, and 23 is 5-methylcytosine;
SEQ ID NO:27, wherein each of nucleotides 6, 10, and 18 comprises 5-
methylcytosine;
SEQ ID NO:28, wherein each of nucleotides 2, 4, 12, 14, 15, and 17 is 5-
methylcytosine;
SEQ ID NO:30, wherein each of nucleotides 2, 4, 18, 19, and 20 is 5-
methylcytosine;
SEQ ID NO:31, wherein each of nucleotides 6, 7, 8, 13, 23, 24, and 26 is 5-
methylcytosine;
SEQ ID NO:32, wherein each of nucleotides 5, 11, 12, and 15 is 5-
methylcytosine;
SEQ ID NO:36, wherein each of nucleotides 2, 3, 4, 16, 18, 19, and 22 is 5-
methylcytosine;
SEQ ID NO:38, wherein each of nucleotides 4, 6, 7, and 8 is 5-methylcytosine;
SEQ ID NO:39, wherein each of nucleotides 2, 9, 12, 19, 22, 24, and 25 is 5-
methylcytosine;
SEQ ID NO:40, wherein each of nucleotides 4, 13, 18, and 22 is 5-
methylcytosine;
SEQ ID NO:42;
SEQ ID NO:43, wherein each of nucleotides 2,9, 12, 16, 17, 22, 23, and 26 is 5-
methylcytosine;
SEQ ID NO:44, wherein each of nucleotides 7,9, 13, and 15 is 5-methylcytosine;
SEQ ID NO:45, wherein each of nucleotides 3, 6, 8, and 17 is 5-methylcytosine;
and
SEQ ID NO:47, wherein each of nucleotides 11, 16, and 17 is 5-methylcytosine.
11
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[0032] Also provided herein is a kit comprising the set of oligonucleotides of
any one of the
above embodiments or the oligonucleotide of any one of the above embodiments.
[0033] Also provided herein is a reaction mixture comprising the set of
oligonucleotides of
any one of the above embodiments or the oligonucleotide of any one of the
above
embodiments.
[0034] Also provided herein is a multiplex method, comprising:
(1) contacting a sample, said sample suspected of containing at least one
enteric
pathogen, with the set of oligonucleotides of any one of the preceding
embodiments;
(2) performing an in vitro nucleic acid amplification reaction, wherein any
Salmonella, C.
jg.uni, C. coli, Shigella, and STEC target nucleic acid, if present in said
sample, is used as a
template for generating one or more amplification products corresponding to
the Salmonella,
C. .guni, C. coli, S higella, and STEC target regions; and
(3) detecting the presence or absence of the one or more amplification
products,
thereby determining the presence or absence of at least one of Salmonella, C.
.guni, C. coli,
Shigella, and STEC in said sample.
[0035] In some embodiments, step (3) of the multiplex method comprises:
contacting the sample with at least one of the Salmonella detection probe, the
C. .guni
detection probe, the C. coli detection probe, the Shigella detection probe,
and the STEC
detection probe;
performing electrophoresis on the sample; or
determining the sequence of the one or more amplification product, if present.
[0036] Also provided herein is a method for synthesizing an oligonucleotide,
comprising the
steps of:
(a) obtaining a solid support comprising at least one nucleobase residue,
wherein at least
one nucleobase residue is covalently bound at a 3' position to the solid
support;
(b) coupling a 5' position of the nucleobase residue furtherest from the
solid support to a
3' position of another nucleobase residue;
(c) repeating step (b) at least 13 additional times, thereby generating at
least 15
contiguous nucleobase residues coupled to the solid support; and
12
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
(d) cleaving the at least 15 contiguous nucleobase residues generated in
step (c), thereby
obtaining the oligonucleotide,
wherein the oligonucleotide comprises the sequence of any one of:
SEQ ID NO:15, wherein each of nucleotides 7 and 15 is 5-methylcytosine;
SEQ ID NO:16;
SEQ ID NO:19, wherein each of nucleotides 1, 2, 7, 14, 15, 19, and 20 is 5-
methylcytosine;
SEQ ID NO:21, wherein each of nucleotides 13, 17, and 24 is 5-methylcytosine;
SEQ ID NO:23, wherein each of nucleotides 2, 5, 7, and 14 is 5-methylcytosine;
SEQ ID NO:25, wherein each of nucleotides 7,9, 13, and 15 is 5-methylcytosine;
SEQ ID NO:26, wherein each of nucleotides 9, 18, and 23 is 5-methylcytosine;
SEQ ID NO:27, wherein each of nucleotides 6, 10, and 18 comprises 5-
methylcytosine;
SEQ ID NO:28, wherein each of nucleotides 2, 4, 12, 14, 15, and 17 is 5-
methylcytosine;
SEQ ID NO:30, wherein each of nucleotides 2, 4, 18, 19, and 20 is 5-
methylcytosine;
SEQ ID NO:31, wherein each of nucleotides 6, 7, 8, 13, 23, 24, and 26 is 5-
methylcytosine;
SEQ ID NO:32, wherein each of nucleotides 5, 11, 12, and 15 is 5-
methylcytosine;
SEQ ID NO:36, wherein each of nucleotides 2, 3, 4, 16, 18, 19, and 22 is 5-
methylcytosine;
SEQ ID NO:38, wherein each of nucleotides 4, 6, 7, and 8 is 5-methylcytosine;
SEQ ID NO:39, wherein each of nucleotides 2, 9, 12, 19, 22, 24, and 25 is 5-
methylcytosine;
SEQ ID NO:40, wherein each of nucleotides 4, 13, 18, and 22 is 5-
methylcytosine;
SEQ ID NO:42;
SEQ ID NO:43, wherein each of nucleotides 2,9, 12, 16, 17, 22, 23, and 26 is 5-
methylcytosine;
SEQ ID NO:44, wherein each of nucleotides 7,9, 13, and 15 is 5-methylcytosine;
SEQ ID NO:45, wherein each of nucleotides 3, 6, 8, and 17 is 5-methylcytosine;
SEQ ID NO:47, wherein each of nucleotides 11, 16, and 17 is 5-methylcytosine;
SEQ ID NO:1, wherein each of nucleotides 6, 7, 9, 14, 17, and 24 is 5-
methylcytosine;
SEQ ID NO:2, wherein each of nucleotides 5, 8, 11, 13, 18, and 21 is 5-
methylcytosine;
SEQ ID NO:6, wherein each of nucleotides 3, 7, 8, 15, 20, 24, and 27 is 5-
methylcytosine;
13
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
SEQ ID NO:7, wherein each of nucleotides 3, 4, 18, and 19 is 5-methylcytosine;
SEQ ID NO:9, wherein each of nucleotides 2, 6, 13, 16, 23, 26, 28, and 29 is 5-
methylcytosine;
SEQ ID NO:12, wherein each of nucleotides 4, 11, 12, and 16 is 5-
methylcytosine;
SEQ ID NO:18, wherein each of nucleotides 7 and 12 or each of nucleotides 7,
12, and 25
is 5-methylcytosine;
SEQ ID NO:22, wherein each of nucleotides 5 and 16 is 5-methylcytosine;
SEQ ID NO:37, wherein each of nucleotides 17, 22, 23, and 27 is 5-
methylcytosine; and
SEQ ID NO:46, wherein each of nucleotides 5, 11, and 12 is 5-methylcytosine.
[0037] In some embodiments, the oligonucleotide has a length of from 18 to 32
contiguous
nucleobase residues. In some embodiments, the oligonucleotide has a length of
from 20 to
30 contiguous nucleobase residues.
[0038] Also provided herein is a method for synthesizing a pair of
oligonucleotides,
comprising of synthesizing a first oligonucleotide and synthesizing a second
oligonucleotide,
wherein each of the synthesizing the first oligonucleotide and the
synthesizing the second
oligonucleotide comprises the steps of:
(a) obtaining a solid support comprising at least one nucleobase residue,
wherein at least
one nucleobase residue is covalently bound at a 3' position to the solid
support;
(b) coupling a 5' position of the nucleobase residue furtherest from the
solid support to a
3' position of another nucleobase residue;
(c) repeating step (b) at least 13 additional times, thereby generating at
least 15
contiguous nucleobase residues coupled to the solid support; and
(d) cleaving at least 15 contiguous nucleobase residues generated in step
(c), thereby
obtaining the oligonucleotide, and
wherein the first oligonucleotide and the second oligonucleotide respectively
comprise the
sequence of any one of:
SEQ ID NO:12 and SEQ ID NO:14;
SEQ ID NO:21 and SEQ ID NO:47;
SEQ ID NO:38 and SEQ ID NO:36;
14
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
SEQ ID NO:35 and SEQ ID NO:40;
SEQ ID NO:12 and SEQ ID NO:28;
SEQ ID NO:42 and SEQ ID NO:31;
SEQ ID NO:41 and SEQ ID NO:27;
SEQ ID NO:11 and SEQ ID NO:19;
SEQ ID NO:8 and SEQ ID NO:10;
SEQ ID NO:15 and SEQ ID NO:17;
SEQ ID NO:34 and SEQ ID NO:22;
SEQ ID NO:32 and SEQ ID NO:33;
SEQ ID NO:49 and SEQ ID NO:3;
SEQ ID NO:20 and SEQ ID NO:3; and
SEQ ID NO:4 and SEQ ID NO:7.
[0039] In some embodiments, each of the first oligonucleotide and the second
oligonucleotide have lengths of from 18 to 32 contiguous nucleobase residues.
In some
embodiments, each of the first oligonucleotide and the second oligonucleotide
have lengths
of from 20 to 30 contiguous nucleobase residues.
[0040] Accordingly, the following embodiments are among those provided by the
disclosure.
[0041] Embodiment 1 is a set of oligonucleotides for determining the presence
or absence of
at least one enteric pathogen, said set of oligonucleotides comprising at
least one of (a)-(e):
(a) a Salmonella-specific amplification oligomer set comprising first and
second
oligomers respectively comprising target-hybridizing sequences substantially
corresponding
to the nucleotide sequences of: (i) SEQ ID NO:12 and SEQ ID NO:14; SEQ ID
NO:21 and SEQ ID NO:47; SEQ ID NO:38 and SEQ ID NO:36; (iv) SEQ ID NO:35
and SEQ ID NO:40; (v) SEQ ID NO:12 and SEQ ID NO:28; (vi) SEQ ID NO:42 and
SEQ ID NO:31; or (vii) SEQ ID NO:41 and SEQ ID NO:27;
(b) a C. jg.uni-specific amplification oligomer set comprising first and
second
oligomers respectively comprising target-hybridizing sequences substantially
corresponding
to the nucleotide sequences of: (i) SEQ ID NO:11 and SEQ ID NO:19;
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
(c) a C. co/i-specific amplification oligomer set comprising first and
second
oligomers respectively comprising target-hybridizing sequences substantially
corresponding
to the nucleotide sequences of: (i) SEQ ID NO:8 and SEQ ID NO:10;
(d) a Shigella-specific amplification oligomer set comprising first and
second
oligomers respectively comprising target-hybridizing sequences substantially
corresponding
to the nucleotide sequences of: (i) SEQ ID NO:15 and SEQ ID NO:17; SEQ ID
NO:34 and SEQ ID NO:22; or (iii) SEQ ID NO:32 and SEQ ID NO:33; and
(e) a Shigatoxigenic E. co/i (STEC)-specific amplification oligomer set
comprising
first and second oligomers respectively comprising target-hybridizing
sequences substantially
corresponding to the nucleotide sequences of: (i) SEQ ID NO:20 and SEQ ID
NO:3; (ii)
SEQ ID NO:49 and SEQ ID NO:3; or (iii) SEQ ID NO:4 and SEQ ID NO:7.
[0042] Embodiment 2 is the set of oligonucleotides of embodiment 1, comprising
the
Sabnonella-specific amplification oligomer set.
[0043] Embodiment 3 is the set of oligonucleotides of embodiment 2, wherein
the Salmonella-
specific amplification oligomer set comprises first and second oligomers
respectively
comprising target-hybridizing sequences substantially corresponding to the
nucleotide
sequences of SEQ ID NO:21 and SEQ ID NO:47.
[0044] Embodiment 4 is the set of oligonucleotides of embodiment 2, wherein
the Salmonella-
specific amplification oligomer set comprises first and second oligomers
respectively
comprising target-hybridizing sequences substantially corresponding to the
nucleotide
sequences of SEQ ID NO:38 and SEQ ID NO:36.
[0045] Embodiment 5 is the set of oligonucleotides of embodiment 2, wherein
the Salmonella-
specific amplification oligomer set comprises first and second oligomers
respectively
comprising target-hybridizing sequences substantially corresponding to the
nucleotide
sequences of SEQ ID NO:35 and SEQ ID NO:40.
[0046] Embodiment 6 is the set of oligonucleotides of embodiment 2, wherein
the Salmonella-
specific amplification oligomer set comprises first and second oligomers
respectively
comprising target-hybridizing sequences substantially corresponding to the
nucleotide
sequences of SEQ ID NO:12 and SEQ ID NO:28.
16
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[0047] Embodiment 7 is the set of oligonucleotides of embodiment 2, wherein
the Salmonella-
specific amplification oligomer set comprises first and second oligomers
respectively
comprising target-hybridizing sequences substantially corresponding to the
nucleotide
sequences of SEQ ID NO:42 and SEQ ID NO:31.
[0048] Embodiment 8 is the set of oligonucleotides of embodiment 2, wherein
the Salmonella-
specific amplification oligomer set comprises first and second oligomers
respectively
comprising target-hybridizing sequences substantially corresponding to the
nucleotide
sequences of SEQ ID NO:41 and SEQ ID NO:27.
[0049] Embodiment 9 is the set of oligonucleotides of any one of the preceding
embodiments, comprising the C. jg.uni-specific amplification oligomer set.
[0050] Embodiment 10 is the set of oligonucleotides of any one of the
preceding
embodiments, comprising the C. co/i-specific amplification oligomer set.
[0051] Embodiment 11 is the set of oligonucleotides of any one of the
preceding
embodiments, comprising the Shigeila-specific amplification oligomer set.
[0052] Embodiment 12 is the set of oligonucleotides of embodiment 11, wherein
the Shigella-
specific amplification oligomer set comprises first and second oligomers
respectively
comprising target-hybridizing sequences substantially corresponding to the
nucleotide
sequences of SEQ ID NO:15 and SEQ ID NO:17.
[0053] Embodiment 13 is the set of oligonucleotides of embodiment 11, wherein
the Shigella-
specific amplification oligomer set comprises first and second oligomers
respectively
comprising target-hybridizing sequences substantially corresponding to the
nucleotide
sequences of SEQ ID NO:34 and SEQ ID NO:22.
[0054] Embodiment 14 is the set of oligonucleotides of embodiment 11, wherein
the Shigella-
specific amplification oligomer set comprises first and second oligomers
respectively
comprising target-hybridizing sequences substantially corresponding to the
nucleotide
sequences of SEQ ID NO:32 and SEQ ID NO:33.
[0055] Embodiment 15 is the set of oligonucleotides of any one of the
preceding
embodiments, comprising the STEC-specific amplification oligomer set.
17
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[0056] Embodiment 16 is the set of oligonucleotides of any one of the
preceding
embodiments, comprising at least two of the Salmonella-specific amplification
oligomer set,
the C./Owi-specific amplification oligomer set, the C. co/i-specific
amplification oligomer set,
the Shigella-specific amplification oligomer set, and the STEC-specific
amplification oligomer
set.
[0057] Embodiment 17 is the set of oligonucleotides of any one of the
preceding
embodiments, comprising at least three of the Salmonella-specific
amplification oligomer set,
the C./Oni-specific amplification oligomer set, the C. co/i-specific
amplification oligomer set,
the Shigella-specific amplification oligomer set, and the STEC-specific
amplification oligomer
set.
[0058] Embodiment 18 is the set of oligonucleotides of any one of the
preceding
embodiments, comprising at least four of the Salmonella-specific amplification
oligomer set,
the C./Oni-specific amplification oligomer set, the C. co/i-specific
amplification oligomer set,
the Shigella-specific amplification oligomer set, and the STEC-specific
amplification oligomer
set.
[0059] Embodiment 19 is the set of oligonucleotides of any one of the
preceding
embodiments, comprising the Salmonella-specific amplification oligomer set,
the C. .guni-
specific amplification oligomer set, the C. co/i-specific amplification
oligomer set, the S higella-
specific amplification oligomer set, and the STEC-specific amplification
oligomer set.
[0060] Embodiment 20 is the set of oligonucleotides of the immediately
preceding
embodiment, wherein
the Salmonella-specific amplification oligomer set comprises first and second
oligomers respectively comprising target-hybridizing sequences substantially
corresponding
to the nucleotide sequences of SEQ ID NO:12 and SEQ ID NO:14;
the C./Oni-specific amplification oligomer set comprises first and second
oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of SEQ ID NO:11 and SEQ ID NO:19;
18
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
the C. coll-specific amplification oligomer set comprises first and second
oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of SEQ ID NO:8 and SEQ ID NO:10;
the Shigella-specific amplification oligomer set comprises first and second
oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of SEQ ID NO:15 and SEQ ID NO:17; and
the STEC-specific amplification oligomer set comprises first and second
oligomers
respectively comprising target-hybridizing sequences substantially
corresponding to the
nucleotide sequences of (i) SEQ ID NO:20 and SEQ ID NO:3; and (ii) SEQ ID NO:4
and
SEQ ID NO:7.
[0061] Embodiment 21 is the set of oligonucleotides of any one of embodiments
2-20, further
comprising:
a Salmonella detection probe, comprising a target-hybridizing sequence
substantially
corresponding to the nucleotide sequence of:
SEQ ID NO:13 if the Salmonella-specific amplification oligomer set comprises
first and second oligomers respectively comprising target-hybridizing
sequences substantially corresponding to the nucleotide sequences of SEQ
ID NO:12 and SEQ ID NO:14;
SEQ ID NO:13 if the Salmonella-specific amplification oligomer set comprises
first and second oligomers respectively comprising target-hybridizing
sequences substantially corresponding to the nucleotide sequences of SEQ
ID NO:12 and SEQ ID NO:28;
SEQ ID NO:45 if the Salmonella-specific amplification oligomer set comprises
first and second oligomers respectively comprising target-hybridizing
sequences substantially corresponding to the nucleotide sequences of SEQ
ID NO:21 and SEQ ID NO:47;
SEQ ID NO:44, SEQ ID NO:26, or SEQ ID NO:25 if the Salmonella-specific
amplification oligomer set comprises first and second oligomers respectively
19
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
comprising target-hybridizing sequences substantially corresponding to the
nucleotide sequences of SEQ ID NO:38 and SEQ ID NO:36;
SEQ ID NO:30 if the Salmonella-specific amplification oligomer set comprises
first and second oligomers respectively comprising target-hybridizing
sequences substantially corresponding to the nucleotide sequences of SEQ
ID NO:35 and SEQ ID NO:40;
SEQ ID NO:23 if the Salmonella-specific amplification oligomer set comprises
first and second oligomers respectively comprising target-hybridizing
sequences substantially corresponding to the nucleotide sequences of SEQ
ID NO:42 and SEQ ID NO:31; or
SEQ ID NO:43 if the Salmonella-specific amplification oligomer set comprises
first and second oligomers respectively comprising target-hybridizing
sequences substantially corresponding to the nucleotide sequences of SEQ
ID NO:41 and SEQ ID NO:27.
[0062] Embodiment 22 is the set of oligonucleotides of embodiment 21, wherein
in SEQ ID
NO:23, one or more, or each of nucleotides 2, 5, 7, and 14 comprises 5-
methylcytosine.
[0063] Embodiment 23 is the set of oligonucleotides of embodiment 21, wherein
in SEQ ID
NO:25, one or more, or each of nucleotides 7,9, 13, and 15 comprises 5-
methylcytosine.
[0064] Embodiment 24 is the set of oligonucleotides of embodiment 21, wherein
in SEQ ID
NO:26, one or more, or each of nucleotides 9, 18, and 23 comprises 5-
methylcytosine.
[0065] Embodiment 25 is the set of oligonucleotides of embodiment 21, wherein
in SEQ ID
NO:27, one or more, or each of nucleotides 6, 10, and 18 comprises 5-
methylcytosine.
[0066] Embodiment 26 is the set of oligonucleotides of embodiment 21, wherein
in SEQ ID
NO:30, one or more, or each of nucleotides 2,4, 18, 19, and 20 comprises 5-
methylcytosine.
[0067] Embodiment 27 is the set of oligonucleotides of embodiment 21, wherein
in SEQ ID
NO:43, one or more, or each of nucleotides 2,9, 12, 16, 17, 22, 23, and 26
comprises 5-
methylcytosine.
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[0068] Embodiment 28 is the set of oligonucleotides of embodiment 21, wherein
in SEQ ID
NO:44, one or more, or each of nucleotides 7,9, 13, and 15 comprises 5-
methylcytosine.
[0069] Embodiment 29 is the set of oligonucleotides of embodiment 21, wherein
in SEQ ID
NO:45, one or more, or each of nucleotides 3, 6, 8, and 17 comprises 5-
methylcytosine.
[0070] Embodiment 30 is the set of oligonucleotides of any one of embodiments
9-27, further
comprising a C. jg.uni detection probe, the C. .guni detection probe
comprising a target-
hybridizing sequence substantially corresponding to the nucleotide sequence of
SEQ ID
NO:18.
[0071] Embodiment 31 is the set of oligonucleotides of embodiment 29, wherein
in SEQ ID
NO:18, one or more of nucleotides 7, 12, and 25, or each of nucleotides 7 and
12, or each of
nucleotides 7, 12, and 25 comprises 5-methylcytosine.
[0072] Embodiment 32 is the set of oligonucleotides of any one of embodiments
10-30,
further comprising a C. co/i detection probe, the C. co/i detection probe
comprising a target-
hybridizing sequence substantially corresponding to the nucleotide sequence of
SEQ ID
NO:9, SEQ ID NO:37, or SEQ ID NO:39.
[0073] Embodiment 33 is the set of oligonucleotides of embodiment 31, wherein
in SEQ ID
NO:9, one or more, or each of nucleotides 2, 6, 13, 16, 23, 26, 28, and 29
comprises 5-
methylcytosine.
[0074] Embodiment 34 is the set of oligonucleotides of embodiment 31, wherein
in SEQ ID
NO:37, one or more, or each of nucleotides 17, 22, 23, and 27 comprises 5-
methylcytosine.
[0075] Embodiment 35 is the set of oligonucleotides of embodiment 31, wherein
in SEQ ID
NO:39, one or more, or each of nucleotides 2,9, 12, 19, 22, 24, and 25
comprises 5-
methylcytosine.
[0076] Embodiment 36 is the set of oligonucleotides of any one of embodiments
11-35,
further comprising:
a Shigella detection probe, the Shigella detection probe comprising a target-
hybridizing
sequence substantially corresponding to the nucleotide sequence of
SEQ ID NO:16 if the Shigella-specific amplification oligomer set comprises
first
and second oligomers respectively comprising target-hybridizing sequences
21
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
substantially corresponding to the nucleotide sequences of SEQ ID NO:15
and SEQ ID NO:17;
SEQ ID NO:46 or SEQ ID NO:29 if the Shigeila-specific amplification oligomer
set comprises first and second oligomers respectively comprising target-
hybridizing sequences substantially corresponding to the nucleotide
sequences of SEQ ID NO:34 and SEQ ID NO:22; or
SEQ ID NO:24 if the Shigella-specific amplification oligomer set comprises
first
and second oligomers respectively comprising target-hybridizing sequences
substantially corresponding to the nucleotide sequences of SEQ ID NO:32
and SEQ ID NO:33.
[0077] Embodiment 37 is the set of oligonucleotides of embodiment 36, wherein
in SEQ ID
NO:46, each of nucleotides 5, 11, and 12 comprises 5-methylcytosine.
[0078] Embodiment 38 is the set of oligonucleotides of any one of embodiments
15-37,
further comprising:
a STEC detection probe, the STEC detection probe comprising a target-
hybridizing
sequence substantially corresponding to the nucleotide sequence of
SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:48 if the STEC-specific
amplification oligomer set comprises first and second oligomers respectively
comprising target-hybridizing sequences substantially corresponding to the
nucleotide sequences of SEQ ID NO:20 and SEQ ID NO:3;
SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:48 if the STEC-specific
amplification oligomer set comprises first and second oligomers respectively
comprising target-hybridizing sequences substantially corresponding to the
nucleotide sequences of SEQ ID NO:49 and SEQ ID NO:3; or
SEQ ID NO:5 or SEQ ID NO:6 if the STEC-specific amplification oligomer set
comprises first and second oligomers respectively comprising target-
hybridizing sequences substantially corresponding to the nucleotide
sequences of SEQ ID NO:4 and SEQ ID NO:7.
22
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[0079] Embodiment 39 is the set of oligonucleotides of embodiment 38, wherein
in SEQ ID
NO:1, one or more, or each of nucleotides 6, 7,9, 14, 17, and 24 comprises 5-
methylcytosine.
[0080] Embodiment 40 is the set of oligonucleotides of embodiment 38, wherein
in SEQ ID
NO:2, one or more, or each of nucleotides 5, 8, 11, 13, 18, and 21 comprises 5-
methylcytosine.
[0081] Embodiment 41 is the set of oligonucleotides of embodiment 38, wherein
in SEQ ID
NO:6, one or more, or each of nucleotides 3,7, 8, 15, 20, 24, and 27 comprises
5-
methylcytosine.
[0082] Embodiment 42 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:15, one or more, or each of nucleotides 7
and 15
comprises 5-methylcytosine.
[0083] Embodiment 43 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:19, one or more, or each of nucleotides 1,
2, 7, 14,
15, 19, and 20 comprises 5-methylcytosine.
[0084] Embodiment 44 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:21, one or more, or each of nucleotides 13,
17, and
24 comprises 5-methylcytosine.
[0085] Embodiment 45 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:28, one or more, or each of nucleotides 2,
4, 12, 14,
15, and 17 comprises 5-methylcytosine.
[0086] Embodiment 46 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:31, one or more, or each of nucleotides 6,
7, 8, 13,
23, 24, and 26 comprises 5-methylcytosine.
[0087] Embodiment 47 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:32, one or more, or each of nucleotides 5,
11, 12,
and 15 comprises 5-methylcytosine.
23
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[0088] Embodiment 48 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:36, one or more, or each of nucleotides 2,
3, 4, 16,
18, 19, and 22 comprises 5-methylcytosine.
[0089] Embodiment 49 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:38, one or more, or each of nucleotides 4,
6, 7, and 8
comprises 5-methylcytosine.
[0090] Embodiment 50 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:40, one or more, or each of nucleotides 4,
13, 18,
and 22 comprises 5-methylcytosine.
[0091] Embodiment 51 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:47, one or more, or each of nucleotides 11,
16, and
17 comprises 5-methylcytosine.
[0092] Embodiment 52 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:7, one or more, or each of nucleotides 3, 4,
18, and
19 comprises 5-methylcytosine.
[0093] Embodiment 53 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:12, one or more, or each of nucleotides 4,
11, 12,
and 16 comprises 5-methylcytosine.
[0094] Embodiment 54 is the set of oligonucleotides of any one of the
preceding
embodiments, wherein in SEQ ID NO:22, each of nucleotides 5 and 16 comprises 5-
methylcytosine.
[0095] Embodiment 55 is the set of oligonucleotides of any one of embodiments
21-54,
wherein one or more, or each, of the detection probes comprises a fluorescent
dye
compound.
[0096] Embodiment 56 is the set of oligonucleotides of the immediately
preceding
embodiment, wherein each of the detection probes further comprises a non-
fluorescent
quenching dye compound.
24
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[0097] Embodiment 57 is an oligonucleotide for determining the presence or
absence of at
least one enteric pathogen, wherein the oligonucleotide comprises the sequence
of any one
of:
SEQ ID NO:15, wherein each of nucleotides 7 and 15 comprises 5-methylcytosine;
SEQ ID NO:16;
SEQ ID NO:19, wherein each of nucleotides 1, 2, 7, 14, 15, 19, and 20
comprises 5-
methylcytosine;
SEQ ID NO:21, wherein each of nucleotides 13, 17, and 24 comprises 5-
methylcytosine;
SEQ ID NO:23, wherein each of nucleotides 2, 5, 7, and 14 comprises 5-
methylcytosine;
SEQ ID NO:25, wherein each of nucleotides 7, 9, 13, and 15 comprises 5-
methylcytosine;
SEQ ID NO:26, wherein each of nucleotides 9, 18, and 23 comprises 5-
methylcytosine;
SEQ ID NO:27, wherein each of nucleotides 6, 10, and 18 comprises 5-
methylcytosine;
SEQ ID NO:28, wherein each of nucleotides 2,4, 12, 14, 15, and 17 comprises 5-
methylcytosine;
SEQ ID NO:30, wherein each of nucleotides 2, 4, 18, 19, and 20 comprises 5-
methylcytosine;
SEQ ID NO:31, wherein each of nucleotides 6, 7, 8, 13, 23, 24, and 26
comprises 5-
methylcytosine;
SEQ ID NO:32, wherein each of nucleotides 5, 11, 12, and 15 comprises 5-
methylcytosine;
SEQ ID NO:36, wherein each of nucleotides 2, 3, 4, 16, 18, 19, and 22
comprises 5-
methylcytosine;
SEQ ID NO:38, wherein each of nucleotides 4, 6, 7, and 8 comprises 5-
methylcytosine;
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
SEQ ID NO:39, wherein each of nucleotides 2, 9, 12, 19, 22, 24, and 25
comprises 5-
methylcytosine;
SEQ ID NO:40, wherein each of nucleotides 4, 13, 18, and 22 comprises 5-
methylcytosine;
SEQ ID NO:42;
SEQ ID NO:43, wherein each of nucleotides 2,9, 12, 16, 17, 22, 23, and 26
comprises 5-methylcytosine;
SEQ ID NO:44, wherein each of nucleotides 7, 9, 13, and 15 comprises 5-
methylcytosine;
SEQ ID NO:45, wherein each of nucleotides 3, 6, 8, and 17 comprises 5-
methylcytosine;
SEQ ID NO:47, wherein each of nucleotides 11, 16, and 17 comprises 5-
methylcytosine;
SEQ ID NO:1, wherein each of nucleotides 6, 7, 9, 14, 17, and 24 comprises 5-
methylcytosine;
SEQ ID NO:2, wherein each of nucleotides 5, 8, 11, 13, 18, and 21 comprises 5-
methylcytosine;
SEQ ID NO:6, wherein each of nucleotides 3, 7, 8, 15, 20, 24, and 27 comprises
5-
methylcytosine;
SEQ ID NO:7, wherein each of nucleotides 3, 4, 18, and 19 comprises 5-
methylcytosine;
SEQ ID NO:9, wherein each of nucleotides 2, 6, 13, 16, 23, 26, 28, and 29
comprises
5-methylcytosine;
SEQ ID NO:12, wherein each of nucleotides 4, 11, 12, and 16 comprises 5-
methylcytosine;
SEQ ID NO:18, wherein each of nucleotides 7 and 12 or each of nucleotides 7,
12,
and 25 comprises 5-methylcytosine;
SEQ ID NO:22, wherein each of nucleotides 5 and 16 comprises 5-methylcytosine;
26
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
SEQ ID NO:37, wherein each of nucleotides 17, 22, 23, and 27 comprises 5-
methylcytosine; and
SEQ ID NO:46, wherein each of nucleotides 5, 11, and 12 comprises 5-
methylcytosine.
[0098] Embodiment 58 is the oligonucleotide of the immediately preceding
embodiment,
wherein the oligonucleotide comprises the sequence of any one of:
SEQ ID NO:15, wherein each of nucleotides 7 and 15 comprises 5-methylcytosine;
SEQ ID NO:16;
SEQ ID NO:19, wherein each of nucleotides 1, 2, 7, 14, 15, 19, and 20
comprises 5-
methylcytosine;
SEQ ID NO:21, wherein each of nucleotides 13, 17, and 24 comprises 5-
methylcytosine;
SEQ ID NO:23, wherein each of nucleotides 2, 5, 7, and 14 comprises 5-
methylcytosine;
SEQ ID NO:25, wherein each of nucleotides 7, 9, 13, and 15 comprises 5-
methylcytosine;
SEQ ID NO:26, wherein each of nucleotides 9, 18, and 23 comprises 5-
methylcytosine;
SEQ ID NO:27, wherein each of nucleotides 6, 10, and 18 comprises 5-
methylcytosine;
SEQ ID NO:28, wherein each of nucleotides 2,4, 12, 14, 15, and 17 comprises 5-
methylcytosine;
SEQ ID NO:30, wherein each of nucleotides 2, 4, 18, 19, and 20 comprises 5-
methylcytosine;
SEQ ID NO:31, wherein each of nucleotides 6, 7, 8, 13, 23, 24, and 26
comprises 5-
methylcytosine;
SEQ ID NO:32, wherein each of nucleotides 5, 11, 12, and 15 comprises 5-
methylcytosine;
27
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
SEQ ID NO:36, wherein each of nucleotides 2, 3, 4, 16, 18, 19, and 22
comprises 5-
methylcytosine;
SEQ ID NO:38, wherein each of nucleotides 4, 6, 7, and 8 comprises 5-
methylcytosine;
SEQ ID NO:39, wherein each of nucleotides 2, 9, 12, 19, 22, 24, and 25
comprises 5-
methylcytosine;
SEQ ID NO:40, wherein each of nucleotides 4, 13, 18, and 22 comprises 5-
methylcytosine;
SEQ ID NO:42;
SEQ ID NO:43, wherein each of nucleotides 2,9, 12, 16, 17, 22, 23, and 26
comprises 5-methylcytosine;
SEQ ID NO:44, wherein each of nucleotides 7, 9, 13, and 15 comprises 5-
methylcytosine;
SEQ ID NO:45, wherein each of nucleotides 3, 6, 8, and 17 comprises 5-
methylcytosine; and
SEQ ID NO:47, wherein each of nucleotides 11, 16, and 17 comprises 5-
methylcytosine.
[0099] Embodiment 59 is a kit comprising the set of oligonucleotides of any
one of
embodiments 1-56 or the oligonucleotide of any one of embodiments 57-58.
[00100] Embodiment 60 is a reaction mixture comprising the set of
oligonucleotides of any
one of embodiments 1-55 or the oligonucleotide of any one of embodiments 57-
58.
[00101] Embodiment 61 is the reaction mixture of the immediately preceding
embodiment,
further comprising a-cyclodextrin or polysorbate 20.
[00102] Embodiment 62 is the reaction mixture of embodiment 60 or 61, further
comprising
a-cyclodextrin and polysorbate 20.
[00103] Embodiment 63 is the reaction mixture of embodiment 61 or 62, wherein
the
concentration of a-cyclodextrin in the reaction mixture is from about 10 mg/mL
to about 40
mg/mL.
28
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[00104] Embodiment 64 is the reaction mixture of any one of embodiments 61-63,
wherein
the concentration of a-cyclodextrin in the reaction mixture is from about 16
mg/mL to
about 30 mg/mL, from about 15 mg/mL to about 20 mg/mL, or from about 10 mg/mL
to
about 15 mg/mL.
[00105] Embodiment 65 is the reaction mixture of any one of embodiments 61-64,
wherein
the concentration of a-cyclodextrin in the reaction mixture is about 20 mg/mL,
about 17.5
mg/mL, or about 12.5 mg/mL.
[00106] Embodiment 66 is the reaction mixture of any one of embodiments 61-65,
wherein
the concentration of polysorbate 20 in the reaction mixture is from about
0.002% to about
0.05% (y/y).
[00107] Embodiment 67 is the reaction mixture of any one of embodiments 61-66,
wherein
the concentration of polysorbate 20 in the reaction mixture is from about
0.003% to about
0.03% (y/y).
[00108] Embodiment 68 is the reaction mixture of any one of embodiments 61-67,
wherein
the concentration of polysorbate 20 in the reaction mixture is about 0.0042%
(y/v), about
0.0035% (y/v), about 0.0026% (y/y), or about 0.02% (y/y).
[00109] Embodiment 69 is the reaction mixture of any one of embodiments 61-68,
further
comprising a detergent.
[00110] Embodiment 70 is the reaction mixture of the immediately preceding
embodiment,
wherein the detergent comprises sodium dodecyl sulfate.
[00111] Embodiment 71 is the reaction mixture of embodiment 69 or 70, wherein
the
concentration of the detergent in the reaction mixture is from about 3 mg/mL
to 300
mg/mL.
[00112] Embodiment 72 is the reaction mixture of any one of embodiments 69-71,
wherein
the concentration of the detergent in the reaction mixture is from about 10
mg/mL to 100
mg/mL.
[00113] Embodiment 73 is the reaction mixture of any one of embodiments 69-72,
wherein
the concentration of the detergent in the reaction mixture is about 33.3
mg/mL.
[00114] Embodiment 74 is a multiplex method, comprising:
29
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
(1) contacting a sample, said sample suspected of containing the at least one
enteric
pathogen, with the set of oligonucleotides of any one of embodiments 1-56;
(2) performing an in vitro nucleic acid amplification reaction, wherein any
Salmonella,
C..guni, C. coli, Shigella, and STEC target nucleic acid, if present in said
sample, is used as a
template for generating one or more amplification products corresponding to
the Salmonella,
C..guni, C. coli, Shigella, and STEC target regions; and
(3) detecting the presence or absence of the one or more amplification
products,
thereby determining the presence or absence of at least one of Salmonella,
C..guni, C.
coli, S higella, and STEC in said sample.
[00115] Embodiment 74.1 is the multiplex method of the immediately preceding
embodiment, wherein the in vitro nucleic acid amplification reaction occurs in
a reaction
mixture of any one of embodiments 60-73.
[00116] Embodiment 75 is the multiplex method of embodiment 74, wherein (3)
comprises:
contacting the sample with at least one of the Salmonella detection probe, the
C. .guni
detection probe, the C. coli detection probe, the Shigella detection probe,
and the
STEC detection probe;
performing electrophoresis on the sample; or
determining the sequence of the one or more amplification product, if present.
[00117] Embodiment 75.1 is the multiplex method of the immediately preceding
embodiment, wherein the in vitro nucleic acid amplification reaction occurs in
a reaction
mixture of any one of embodiments 60-73.
[00118] Embodiment 76 is a method for synthesizing an oligonucleotide,
comprising the
steps of:
(a) obtaining a solid support comprising at least one nucleobase residue,
wherein
the at least one nucleobase residue is covalently bound at a 3' position to
the solid support;
(b) coupling a 5' position of the nucleobase residue furtherest from the
solid
support to a 3' position of another nucleobase residue;
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
(c) repeating step (b) at least 13 additional times, thereby generating at
least 15
contiguous nucleobase residues coupled to the solid support; and
(d) cleaving the at least 15 contiguous nucleobase residues generated in
step (c),
thereby obtaining the oligonucleotide,
wherein the oligonucleotide comprises the sequence of any one of:
SEQ ID NO:15, wherein each of nucleotides 7 and 15 comprises 5-methylcytosine;
SEQ ID NO:16;
SEQ ID NO:19, wherein each of nucleotides 1, 2, 7, 14, 15, 19, and 20
comprises 5-
methylcytosine;
SEQ ID NO:21, wherein each of nucleotides 13, 17, and 24 comprises 5-
methylcytosine;
SEQ ID NO:23, wherein each of nucleotides 2, 5, 7, and 14 comprises 5-
methylcytosine;
SEQ ID NO:25, wherein each of nucleotides 7, 9, 13, and 15 comprises 5-
methylcytosine;
SEQ ID NO:26, wherein each of nucleotides 9, 18, and 23 comprises 5-
methylcytosine;
SEQ ID NO:27, wherein each of nucleotides 6, 10, and 18 comprises 5-
methylcytosine;
SEQ ID NO:28, wherein each of nucleotides 2,4, 12, 14, 15, and 17 comprises 5-
methylcytosine;
SEQ ID NO:30, wherein each of nucleotides 2, 4, 18, 19, and 20 comprises 5-
methylcytosine;
SEQ ID NO:31, wherein each of nucleotides 6, 7, 8, 13, 23, 24, and 26
comprises 5-
methylcytosine;
SEQ ID NO:32, wherein each of nucleotides 5, 11, 12, and 15 comprises 5-
methylcytosine;
SEQ ID NO:36, wherein each of nucleotides 2, 3, 4, 16, 18, 19, and 22
comprises 5-
methylcytosine;
31
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
SEQ ID NO:38, wherein each of nucleotides 4, 6, 7, and 8 comprises 5-
methylcytosine;
SEQ ID NO:39, wherein each of nucleotides 2, 9, 12, 19, 22, 24, and 25
comprises 5-
methylcytosine;
SEQ ID NO:40, wherein each of nucleotides 4, 13, 18, and 22 comprises 5-
methylcytosine;
SEQ ID NO:42;
SEQ ID NO:43, wherein each of nucleotides 2,9, 12, 16, 17, 22, 23, and 26
comprises 5-methylcytosine;
SEQ ID NO:44, wherein each of nucleotides 7, 9, 13, and 15 comprises 5-
methylcytosine;
SEQ ID NO:45, wherein each of nucleotides 3, 6, 8, and 17 comprises 5-
methylcytosine;
SEQ ID NO:47, wherein each of nucleotides 11, 16, and 17 comprises 5-
methylcytosine;
SEQ ID NO:1, wherein each of nucleotides 6, 7, 9, 14, 17, and 24 comprises 5-
methylcytosine;
SEQ ID NO:2, wherein each of nucleotides 5, 8, 11, 13, 18, and 21 comprises 5-
methylcytosine;
SEQ ID NO:6, wherein each of nucleotides 3, 7, 8, 15, 20, 24, and 27 comprises
5-
methylcytosine;
SEQ ID NO:7, wherein each of nucleotides 3, 4, 18, and 19 comprises 5-
methylcytosine;
SEQ ID NO:9, wherein each of nucleotides 2, 6, 13, 16, 23, 26, 28, and 29
comprises
5-methylcytosine;
SEQ ID NO:12, wherein each of nucleotides 4, 11, 12, and 16 comprises 5-
methylcytosine;
SEQ ID NO:18, wherein each of nucleotides 7 and 12 or each of nucleotides 7,
12,
and 25 comprises 5-methylcytosine;
32
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
SEQ ID NO:22, wherein each of nucleotides 5 and 16 comprises 5-methylcytosine;
SEQ ID NO:37, wherein each of nucleotides 17, 22, 23, and 27 comprises 5-
methylcytosine; and
SEQ ID NO:46, wherein each of nucleotides 5, 11, and 12 comprises 5-
methylcytosine.
[00119] Embodiment 77 is the method of embodiment 76, wherein the
oligonucleotide has a
length of from 18 to 32 contiguous nucleobase residues, or from 20 to 30
contiguous
nucleobase residues.
[00120] Embodiment 78 is a method for synthesizing a pair of oligonucleotides,
comprising
synthesizing a first oligonucleotide and synthesizing a second
oligonucleotide,
wherein each of the synthesizing the first oligonucleotide and the
synthesizing the
second oligonucleotide comprises the steps of:
(a) obtaining a solid support comprising at least one nucleobase residue,
wherein the at least one nucleobase residue is covalently bound at a 3'
position to the
solid support;
(b) coupling a 5' position of the nucleobase residue furtherest from the
solid support to a 3' position of another nucleobase residue;
(c) repeating step (b) at least 13 additional times, thereby generating at
least 15 contiguous nucleobase residues coupled to the solid support; and
(d) cleaving the at least 15 contiguous nucleobase residues generated in
step (c), thereby obtaining the oligonucleotide, and
wherein the first oligonucleotide and the the second oligonucleotide
respectively
comprise the sequence of any one of:
SEQ ID NO:12 and SEQ ID NO:14;
SEQ ID NO:21 and SEQ ID NO:47;
SEQ ID NO:38 and SEQ ID NO:36;
SEQ ID NO:35 and SEQ ID NO:40;
33
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
SEQ ID NO:12 and SEQ ID NO:28;
SEQ ID NO:42 and SEQ ID NO:31;
SEQ ID NO:41 and SEQ ID NO:27;
SEQ ID NO:11 and SEQ ID NO:19;
SEQ ID NO:8 and SEQ ID NO:10;
SEQ ID NO:15 and SEQ ID NO:17;
SEQ ID NO:34 and SEQ ID NO:22;
SEQ ID NO:32 and SEQ ID NO:33;
SEQ ID NO:49 and SEQ ID NO:3;
SEQ ID NO:20 and SEQ ID NO:3; and
SEQ ID NO:4 and SEQ ID NO:7.
[00121] Embodiment 79 is the method of embodiment 78, wherein each of the
first
oligonucleotide and the second oligonucleotide have a length of from 18 to 32
contiguous
nucleobase residues, or from 20 to 30 contiguous nucleobase residues.
DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
Definitions
[00122] Before describing the present teachings in detail, it is to be
understood that the
disclosure is not limited to specific compositions or process steps, as such
may vary. It
should be noted that, as used in this specification and the appended claims,
the singular form
"a," "an," and "the" include plural references unless the context clearly
dictates otherwise.
Thus, for example, reference to "an oligomer" includes a plurality of
oligomers and the like.
The conjunction "or" is to be interpreted in the inclusive sense, i.e., as
equivalent to
"and/or," unless the inclusive sense would be unreasonable in the context.
[00123] It will be appreciated that there is an implied "about" prior to the
temperatures,
concentrations, times, etc. discussed in the present disclosure, such that
slight and
insubstantial deviations are within the scope of the present teachings herein.
In general, the
term "about" indicates insubstantial variation in a quantity of a component of
a composition
not having any significant effect on the activity or stability of the
composition. All ranges are
to be interpreted as encompassing the endpoints in the absence of express
exclusions such
34
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
as "not including the endpoints"; thus, for example, "within 10-15" includes
the values 10
and 15. Also, the use of "comprise," "comprises," "comprising," "contain,"
"contains,"
"containing," "include," "includes," and "including" are not intended to be
limiting. It is to
be understood that both the foregoing general description and detailed
description are
exemplary and explanatory only and are not restrictive of the teachings. To
the extent that
any material incorporated by reference is inconsistent with the express
content of this
disclosure, the express content controls.
[00124] Unless specifically noted, embodiments in the specification that
recite "comprising"
various components are also contemplated as "consisting of' or "consisting
essentially of'
the recited components; embodiments in the specification that recite
"consisting of" various
components are also contemplated as "comprising" or "consisting essentially
of" the recited
components; and embodiments in the specification that recite "consisting
essentially of'
various components are also contemplated as "consisting of" or "comprising"
the recited
components (this interchangeability does not apply to the use of these terms
in the claims).
"Consisting essentially of" means that additional component(s), composition(s)
or method
step(s) that do not materially change the basic and novel characteristics of
the compositions
and methods described herein may be included in those compositions or methods.
Such
characteristics include the ability to detect an enteric pathogen's nucleic
acid sequence
present in a sample with specificity that distinguishes the nucleic acid from
other known
pathogens, optionally at a sensitivity that can detect from 75 to 150 CFU/mL
of the enteric
pathogen, and, optionally from about 90 to about 180 minutes or from about 120
to about
150 minutes, and/or from about 30 cycles to about 60 cycles, from about 40
cycles to about
50 cycles, or about 45 cycles, from the beginning of an amplification reaction
when a cycled
amplification reaction is used.
[00125] A "sample" or "specimen," including "biological" or "clinical"
samples, refers to
any material that may contain or is suspected of containing one or more of
Salmonella,
Shigella, Campylobacterjejuni, Campylobacter colt, and STEC, or components
thereof, such as
nucleic acids or fragments of nucleic acids. A sample may be a complex mixture
of
components. Samples include "biological samples" which include any tissue or
material
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
derived from a living or dead mammal or organism, including, for example,
stool, blood,
plasma, serum, blood cells, saliva, mucous and cerebrospinal fluid. A sample
may include
stool from an organism experiencing one or more symptoms of infection by one
or more of
Salmonella, Shigella, Campylobacterjejuni, Campylobacter coli, and STEC. A
sample may also be a
"spiked" sample, such as stool that is from an organism not experiencing any
symptoms of
infection but to which one or more of Salmonella, Shigella,
Campylobacterjejuni, Campylobacter
coli, and STEC is artificially added. Samples may also include samples of in
vitro cell culture
constituents including, for example, conditioned media resulting from the
growth of cells
and tissues in culture medium. The sample may be treated to chemically,
physically or
mechanically to disrupt tissue or cell structure to release intracellular
nucleic acids into a
solution which may contain enzymes, buffers, salts, detergents and the like,
to prepare the
sample for analysis. In one step of the methods described herein, a sample is
provided that is
suspected of containing target nucleic acid of at least one enteric pathogen,
such as
Salmonella, Shigella, C. jejuni, C. coli, and STEC. Accordingly, this step
excludes the physical
step of obtaining the sample from a subject.
[00126] "Nucleic acid" and "polynucleotide" refer to a multimeric compound
comprising
nucleosides or nucleoside analogs which have nitrogenous heterocyclic bases or
base analogs
linked together to form a polynucleotide, including conventional RNA, DNA,
mixed RNA-
DNA, and polymers that are analogs thereof. A nucleic acid "backbone" may be
made up of
a variety of linkages, including one or more of sugar-phosphodiester linkages,
peptide-
nucleic acid bonds ("peptide nucleic acids" or PNA; PCT No. WO 95/32305),
phosphorothioate linkages, methylphosphonate linkages, or combinations
thereof. Sugar
moieties of a nucleic acid may be ribose, deoxyribose, or similar compounds
with
substitutions, e.g., 2' methoxy or 2' halide substitutions. Nitrogenous bases
may be
conventional bases (A, G, C, T, U), analogs thereof (e.g., inosine or others;
see The
Biochemistg of the Nucleic Acids 5-36, Adams et al., ed., 11th ed., 1992),
derivatives of purines or
pyrimidines (e.g., N4-methyl deoxyguanosine, deaza- or aza-purines, deaza- or
aza-
pyrimidines, pyrimidine bases with substituent groups at the 5 or 6 position,
purine bases
with a substituent at the 2, 6, or 8 positions, 2-amino-6-methylaminopurine,
06-
36
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
methylguanine, 4-thio-pyrimidines, 4-amino-pyrimidines, 4-dimethylhydrazine-
pyrimidines,
and 04-alkyl-pyrimidines; US Pat. No. 5,378,825 and PCT No. WO 93/13121).
Nucleic
acids may include one or more "abasic" residues where the backbone includes no
nitrogenous base for position(s) of the polymer (US Pat. No. 5,585,481). A
nucleic acid may
comprise only conventional RNA or DNA sugars, bases and linkages, or may
include both
conventional components and substitutions (e.g., conventional bases with 2'
methoxy
linkages, or polymers containing both conventional bases and one or more base
analogs).
Nucleic acid includes "locked nucleic acid" (LNA), an analogue containing one
or more
LNA nucleotide monomers with a bicyclic furanose unit locked in an RNA
mimicking sugar
conformation, which enhance hybridization affinity toward complementary RNA
and DNA
sequences (Vester and Wengel, 2004, Biochemistg 43(42):13233-41). Embodiments
of
oligomers that may affect stability of a hybridization complex include PNA
oligomers,
oligomers that include 2'-methoxy or 2'-fluoro substituted RNA, or oligomers
that affect the
overall charge, charge density, or steric associations of a hybridization
complex, including
oligomers that contain charged linkages (e.g., phosphorothioates) or neutral
groups (e.g.,
methylphosphonates). 5-methylcytosines may be used in conjunction with any of
the
foregoing backbones/sugars/linkages including RNA or DNA backbones (or
mixtures
thereof) unless otherwise indicated. It is understood that when referring to
ranges for the
length of an oligonucleotide, amplicon, or other nucleic acid, that the range
is inclusive of all
whole numbers (e.g., 19-25 contiguous nucleotides in length includes 19, 20,
21, 22, 23, 24,
and 25).
[00127] "C" or "cytosine" residues include methylated and unmethylated
cytosines unless
the context indicates otherwise.
[00128] An "oligonucleotide" or "oligomer" refers to a nucleic acid of
generally less than
1,000 nucleotides (nt), including those in a size range having a lower limit
of about 2 to 5 nt
and an upper limit of about 500 to 900 nt. Some particular embodiments are
oligonucleotides in a size range with a lower limit of about 5 to 15, 16, 17,
18, 19, or 20 nt
and an upper limit of about 50 to 600 nt, and other particular embodiments are
in a size
range with a lower limit of about 10 to 20 nt and an upper limit of about 22
to 100 nt.
37
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
Oligonucleotides may be purified from naturally occurring sources, but may be
synthesized
by using any well known enzymatic or chemical method. Oligonucleotides may be
referred
to by a functional name (e.g., capture probe, primer or promoter primer) but
those skilled in
the art will understand that such terms refer to oligomers.
[00129] By "amplicon" or "amplification product" is meant a nucleic acid
molecule
generated in a nucleic acid amplification reaction and which is derived from a
target nucleic
acid. An amplicon or amplification product contains a target nucleic acid
sequence that may
be of the same or opposite sense as the target nucleic acid.
[00130] An "amplification oligonucleotide" or "amplification oligomer" refers
to an
oligonucleotide that hybridizes to a target nucleic acid, or its complement,
and participates in
a nucleic acid amplification reaction, e.g., serving as a primer or and
promoter-primer.
Particular amplification oligonucleotides contain at least about 10 contiguous
bases, and
optionally at least 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 contiguous
bases, that are
complementary to a region of the target nucleic acid sequence or its
complementary strand.
The contiguous bases may be at least about 80%, at least about 90%, or
completely
complementary to the target sequence to which the amplification oligomer
binds. One
skilled in the art will understand that the recited ranges include all whole
and rational
numbers within the range (e.g., 92% or 98.377 /0). Particular amplification
oligonucleotides
are about 10 to about 60 bases long and optionally may include modified
nucleotides.
[00131] A "primer" refers to an oligonucleotide that hybridizes to a template
nucleic acid
and has a 3' end that is extended by polymerization. A primer may be
optionally modified,
e.g., by including a 5' region that is non-complementary to the target
sequence. Such
modification can include functional additions, such as tags, promoters, or
other sequences
used or useful for manipulating or amplifying the primer or target
oligonucleotide.
[00132] Within the context of transcription mediated amplification, a primer
modified with
a 5' promoter sequence may be referred to as a "promoter-primer." A person of
ordinary
skill in the art of molecular biology or biochemistry will understand that an
oligonucleotide
that can function as a primer can be modified to include a 5' promoter
sequence and then
38
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
function as a promoter-primer, and, similarly, any promoter-primer can serve
as a primer
with or without its 5' promoter sequence.
[00133] "Nucleic acid amplification" refers to any in vitro procedure that
produces multiple
copies of a target nucleic acid sequence, or its complementary sequence, or
fragments
thereof (i.e., an amplified sequence containing less than the complete target
nucleic acid).
Examples of nucleic acid amplification procedures include transcription
associated methods,
such as transcription-mediated amplification (TMA), nucleic acid sequence-
based
amplification (NASBA) and others (e.g., US Pat. Nos. 5,399,491, 5,554,516,
5,437,990,
5,130,238, 4,868,105, and 5,124,246), replicase-mediated amplification (e.g.,
US Pat. No.
4,786,600), the polymerase chain reaction (PCR) (e.g., US Pat. Nos. 4,683,195,
4,683,202,
and 4,800,159), ligase chain reaction (LCR) (e.g., EP Pat. App. 0320308),
helicase-dependent
amplification (e.g., US Pat. No. 7,282,328), and strand-displacement
amplification (SDA)
(e.g., US Pat. No. 5,422,252). Amplification may be linear or exponential.
Replicase-mediated
amplification uses self-replicating RNA molecules, and a replicase such as QB-
replicase.
PCR amplification uses DNA polymerase, primers, and thermal cycling steps to
synthesize
multiple copies of the two complementary strands of DNA or cDNA. LCR
amplification
uses at least four separate oligonucleotides to amplify a target and its
complementary strand
by using multiple cycles of hybridization, ligation, and denaturation.
Helicase-dependent
amplification uses a helicase to separate the two strands of a DNA duplex
generating single-
stranded templates, followed by hybridization of sequence-specific primers
hybridize to the
templates and extension by DNA polymerase to amplify the target sequence. SDA
uses a
primer that contains a recognition site for a restriction endonuclease that
will nick one strand
of a hemimodified DNA duplex that includes the target sequence, followed by
amplification
in a series of primer extension and strand displacement steps. Particular
embodiments use
PCR or TMA, but it will be apparent to persons of ordinary skill in the art
that
oligonucleotides disclosed herein may be readily used as primers in other
amplification
methods.
[00134] Transcription associated amplification uses a DNA polymerase, an RNA
polymerase, deoxyribonucleoside triphosphates, ribonucleoside triphosphates, a
promoter-
39
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
containing oligonucleotide, and optionally may include other oligonucleotides,
to ultimately
produce multiple RNA transcripts from a nucleic acid template (described in
detail in US
Pat. Nos. 5,399,491 and 5,554,516, Kacian et al., US Pat. No. 5,437,990, Burg
et al., PCT
Nos. WO 88/01302 and WO 88/10315, Gingeras et al., US Pat. No. 5,130,238,
Malek et al.,
US Pat. Nos. 4,868,105 and 5,124,246, Urdea et al., PCT No. WO 94/03472,
McDonough et
al., PCT No. WO 95/03430, and Ryder et al.). Methods that use TMA are
described in detail
previously (US Pat. Nos. 5,399,491 and 5,554,516).
[00135] In cyclic amplification methods that detect amplicons in real-time,
the term
"threshold cycle" (Ct) is a measure of the emergence time of a signal
associated with
amplification of target, and is generally 10x standard deviation of the
normalized reporter
signal. Once an amplification reaches the "threshold cycle," generally there
is considered to
be a positive amplification product of a sequence to which the probe binds.
The identity of
the amplification product can then be determined through methods known to one
of skill in
the art, such as gel electrophoresis, nucleic acid sequencing, and other such
analytical
procedures.
[00136] As used herein, the term "relative fluorescence unit" ("RFU") is a
unit of
measurement of fluorescence intensity. RFU varies with the characteristics of
the detection
means used for the measurement, and can be used as a measurement to compare
relative
intensities between samples and controls.
[00137] "Detection probe" or "probe" refers to an oligonucleotide that
hybridizes
specifically to a target sequence, including an amplified sequence, under
conditions that
promote nucleic acid hybridization, for detection of the target nucleic acid.
Detection may
either be direct (i.e., probe hybridized directly to the target) or indirect
(i.e., a probe
hybridized to an intermediate structure that links the probe to the target). A
probe's target
sequence generally refers to the specific sequence within a larger sequence
which the probe
hybridizes specifically. A detection probe may include target-specific
sequences and a non-
target-complementary sequence. Such non-target-complementary sequences can
include
sequences which will confer a desired secondary or tertiary structure, such as
a hairpin
structure, which can be used to facilitate detection and/or amplification
(e.g., US Pat. Nos.
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
5,118,801, 5,312,728, 6,835,542, and 6,849,412). Probes of a defined sequence
may be
produced by techniques known to those of ordinary skill in the art, such as by
chemical
synthesis, and by in vitro or in vivo expression from recombinant nucleic acid
molecules.$
[00138] As used herein, a nucleic acid "substantially corresponding to" a
specified nucleic
acid sequence, or its complement, means that the oligonucleotide is
sufficiently similar to the
reference nucleic acid sequence such that the oligonucleotide has similar
hybridization
properties to the reference nucleic acid sequence in that it would hybridize
with the same
target nucleic acid sequence under stringent hybridization conditions.
Substantially
corresponding nucleic acids vary by at least one nucleotide from the specified
nucleic acid.
This variation may be stated in terms of a percentage of sequence identity or
complementarity between the nucleic acid and the specified nucleic acid (e.g.,
from less than
100% to about 80%). One skilled in the art will understand that the recited
ranges include all
whole and rational numbers of the range (e.g., 92%, 92.377%, etc).
[00139] By "hybridization" or "hybridize" is meant the ability of two
completely or partially
complementary nucleic acid strands to come together under specified
hybridization assay
conditions in a parallel or antiparallel orientation to form a stable
structure having a double-
stranded region. The two constituent strands of this double-stranded
structure, sometimes
called a hybrid, are held together by hydrogen bonds. Although these hydrogen
bonds most
commonly form between nucleotides containing the bases adenine and thymine or
uracil (A
and T or U) or cytosine and guanine (C and G) on single nucleic acid strands,
base pairing
can also form between bases which are not members of these "canonical" pairs.
Non-
canonical base pairing is well-known in the art. (See, e.g., Adams et al., The
Biochemistg of the
Nucleic Acids (11th ed. 1992).)
[00140] By "preferentially hybridize" is meant that under stringent
hybridization conditions,
an amplification or detection probe oligonucleotide can hybridize to its
target nucleic acid to
form stable oligonucleotide:target hybrid, but not form a sufficient number of
stable
oligonucleotide:non-target hybrids. Amplification and detection
oligonucleotides that
preferentially hybridize to a target nucleic acid are useful to amplify and
detect target nucleic
acids, but not non-targeted organisms, especially phylogenetically closely
related organisms.
41
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
Thus, the oligonucleotide hybridizes to target nucleic acid to a sufficiently
greater extent than
to non-target nucleic acid to enable one having ordinary skill in the art to
accurately amplify
and/or detect the presence (or absence) of nucleic acid derived from the
specified enteric
pathogen as appropriate. In general, reducing the degree of complementarity
between an
oligonucleotide sequence and its target sequence will decrease the degree or
rate of
hybridization of the oligonucleotide to its target region. However, the
inclusion of one or
more non-complementary nucleosides or nucleobases may facilitate the ability
of an
oligonucleotide to discriminate against non-target organisms.
[00141] Preferential hybridization can be measured using techniques known in
the art and
described herein, such as in the examples provided below. In some embodiments,
there is at
least a 10-fold difference between target and non-target hybridization signals
in a test
sample, at least a 100-fold difference, or at least a 1,000-fold difference.
In some
embodiments, non-target hybridization signals in a test sample are no more
than the
background signal level.
[00142] By "stringent hybridization conditions" or "stringent conditions" is
meant
conditions permitting an oligomer to preferentially hybridize to a target
nucleic acid (such as
an enteric pathogen nucleic acid) and not to nucleic acid derived from a
closely related non-
target nucleic acid. While the definition of stringent hybridization
conditions does not vary,
the actual reaction environment that can be used for stringent hybridization
may vary
depending upon factors including the GC content and length of the
oligonucleotide, the
degree of similarity between the oligonucleotide sequence and sequences of non-
target
nucleic acids that may be present in the test sample, and the target sequence.
Hybridization
conditions include the temperature and the composition of the hybridization
reagents or
solutions. Exemplary hybridization assay conditions for amplifying and/or
detecting target
nucleic acids derived from one or more the target enteric pathogens with the
oligonucleotides of the present disclosure correspond to a temperature of
about 60 C when
the salt concentration, such as a monovalent salt, e.g., KC1, is in the range
of about 0.06-
0.09 M. Specific hybridization assay conditions are set forth infra in the
Examples section.
42
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
Other acceptable stringent hybridization conditions could be easily
ascertained by those
having ordinary skill in the art.
[00143] By "assay conditions" is meant conditions permitting stable
hybridization of an
oligonucleotide to a target nucleic acid. Assay conditions do not require
preferential
hybridization of the oligonucleotide to the target nucleic acid.
[00144] "Label" or "detectable label" refers to a moiety or compound joined
directly or
indirectly to a probe that is detected or leads to a detectable signal. Direct
joining may use
covalent bonds or non-covalent interactions (e.g., hydrogen bonding,
hydrophobic or ionic
interactions, and chelate or coordination complex formation) whereas indirect
joining may
use a bridging moiety or linker (e.g., via an antibody or additional
oligonucleotide(s), which
amplify a detectable signal. Any detectable moiety may be used, e.g.,
radionuclide, ligand
such as biotin or avidin, enzyme, enzyme substrate, reactive group,
chromophore such as a
dye or particle (e.g., latex or metal bead) that imparts a detectable color,
luminescent
compound (e.g. bioluminescent, phosphorescent, or chemiluminescent compound),
and
fluorescent compound (i.e., fluorophore). Embodiments of fluorophores include
those that
absorb light in the range of about 495 to 690 nm and emit light in the range
of about 520 to
705 nm, which include those known as FAMTm, TETTm, CAL FLUORTM (Orange or
Red),
and QUASARTM compounds. Fluorophores may be used in combination with a
quencher
molecule that absorbs light when in close proximity to the fluorophore to
diminish
background fluorescence. Such quenchers are well known in the art and include,
e.g.,
BLACK HOLE QUENCHERTM (or BHQTM) or TAMRATm compounds. Particular
embodiments include a "homogeneous detectable label" that is detectable in a
homogeneous
system in which bound labeled probe in a mixture exhibits a detectable change
compared to
unbound labeled probe, which allows the label to be detected without
physically removing
hybridized from unhybridized labeled probe (e.g., US Pat. Nos. 5,283,174,
5,656,207, and
5,658,737). Particular homogeneous detectable labels include chemiluminescent
compounds,
including acridinium ester ("AE") compounds, such as standard AE or AE
derivatives,
which are well known (US Pat. Nos. 5,656,207, 5,658,737, and 5,639,604).
Methods of
synthesizing labels, attaching labels to nucleic acid, and detecting signals
from labels are well
43
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
known (e.g., Sambrook et al., Molecular Cloning, A Laboratog Manual, 2nd ed.
(Cold Spring
Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) at Chapt. 10, and US
Pat. Nos.
5,658,737, 5,656,207, 5,547,842, 5,283,174, and 4,581,333, and EP Pat. App. 0
747 706).
Particular methods of linking an AE compound to a nucleic acid are known
(e.g., US Pat.
No. 5,585,481 and US Pat. No. 5,639,604, see column 10, line 6 to column 11,
line 3, and
Example 8). Particular AE labeling positions are a probe's central region and
near a region of
A/T base pairs, at a probe's 3' or 5' terminus, or at or near a mismatch site
with a known
sequence that is the probe should not detect compared to the desired target
sequence. Other
detectably labeled probes include TaqManTm probes, molecular torches, and
molecular
beacons. TaqManTm probes include a donor and acceptor label wherein
fluorescence is
detected upon enzymatically degrading the probe during amplification in order
to release the
fluorophore from the presence of the quencher. Molecular torches and beacons
exist in
open and closed configurations wherein the closed configuration quenches the
fluorophore
and the open position separates the fluorophore from the quencher to allow
fluorescence.
Hybridization to target opens the otherwise closed probes.
[00145] A "non-extendable" oligonucleotide includes a blocking moiety at or
near its 3'-
terminus to prevent extension. A blocking group near the 3' end is in some
embodiments
within five residues of the 3' end and is sufficiently large to limit binding
of a polymerase to
the oligomer, and other embodiments contain a blocking group covalently
attached to the 3'
terminus. Many different chemical groups may be used to block the 3' end,
e.g., alkyl groups,
non-nucleotide linkers, alkane-diol dideoxynucleotide residues, and
cordycepin. Further
examples of blocking moieties include a 3'-deoxy nucleotide (e.g., a 2',3'-
dideoxy nucleotide);
a 3'-phosphorylated nucleotide; a fluorophore, quencher, or other label that
interferes with
extension; an inverted nucleotide (e.g., linked to the preceding nucleotide
through a 3'-to-3'
phosphodiester, optionally with an exposed 5'-OH or phosphate); or a protein
or peptide
joined to the oligonucleotide so as to prevent further extension of a nascent
nucleic acid
chain by a polymerase. A non-extendable oligonucleotide of the present
disclosure may be at
least 10 bases in length, and may be up to 15, 20, 25, 30, 35, 40, 50 or more
nucleotides in
44
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
length. Non-extendable oligonucleotides that comprise a detectable label can
be used as
probes.
[00146] References, particularly in the claims, to "the sequence of SEQ ID NO:
X" refer to
the base sequence of the corresponding sequence listing entry and do not
require identity of
the backbone (e.g., RNA, 2'-0-Me RNA, or DNA) or base modifications (e.g.,
methylation
of cytosine residues) unless otherwise specifically indicated.
[00147] A "non-Watson Crick" (NWC) position in an oligonucleotide refers to a
position
where the oligonucleotide is configured to hybridize to at least one target
sequence with a
non-Watson Crick pairing, including through the use of inosine (e.g., via the
inosine's
hypoxanthine (I)). Such NWC pairing includes, for example, I-A, I-T, I-C, I-G,
I-U, G-U, G-
T, and G-A (any of the I/A/T/C/G/U can be the base in the oligonucleotide). In
some
embodiments, the NWC position is configured to hybridize via an I-A pair. In
some
embodiments, the NWC position is configured to hybridize via an I-T pair. In
some
embodiments, the NWC position is configured to hybridize via an I-C pair. In
some
embodiments, the NWC position is configured to hybridize via an I-G pair. In
some
embodiments, the NWC position is configured to hybridize via an I-U pair. In
some
embodiments, the NWC position is configured to hybridize via a wobble (G-U) or
purine-
purine (G-A) pair. In some embodiments, the NWC position is configured to
hybridize via a
G-T pair. In some embodiments, the NWC position is configured to hybridize via
a G-U
pair. In some embodiments, the NWC position is configured to hybridize via a G-
A pair.
[00148] Unless defined otherwise, all scientific and technical terms used
herein have the
same meaning as commonly understood by those skilled in the relevant art.
General
definitions may be found in technical books relevant to the art of molecular
biology, e.g.,
DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 2nd ed. (Singleton et al.,
1994, John Wiley & Sons, New York, NY) or THE HARPER COLLINS DICTIONARY OF
BIOLOGY (Hale & Marham, 1991, Harper Perennial, New York, NY).
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
Exemplary compositions, kits, methods, and uses
[00149] The present disclosure provides oligomers, compositions, and kits,
useful for
determining the presence or absence of at least one enteric pathogen, such as
Salmonella, C.
.guni, C. coli, Shigella, and STEC, in a sample.
[00150] In some embodiments, oligonucleotides are provided, e.g., in a kit or
composition.
Oligonucleotides generally comprise a target-hybridizing region, e.g.,
configured to hybridize
specifically to a target nucleic acid of an enteric pathogen. While
oligonucleotides of
different lengths and base composition may be used for amplifying target
nucleic acids, in
some embodiments, oligonucleotides in this disclosure have target-hybridizing
regions from
about 10-60 bases in length, about 14-50 bases in length, about 14-40 bases in
length, about
14-35 bases in length, or about 15-30 bases in length. In some embodiments, an
oligonucleotide comprises a second region of sequence in addition to the
target-hybridizing
region, such as a promoter, which can be located 5' of the target-hybridizing
region. In some
embodiments, an oligonucleotide does not comprise a second region of sequence.
[00151] In some embodiments, a set of oligonucleotides is provided wherein one
oligonucleotide is configured to hybridize to a sense strand of a target
nucleic acid and the
other oligonucleotide is configured to hybridize to an anti-sense strand of a
target nucleic
acid. Such oligonucleotides include amplification oligomer sets (e.g., primer
pairs) for PCR
or other forms of amplification.
[00152] In some embodiments, one or more oligonucleotides, such as a primer
pair or a
primer pair and a third oligonucleotide that is optionally labeled (e.g., for
use as a probe), are
configured to hybridize to a target nucleic acid of one or more enteric
pathogens, including
Salmonella, C. .guni, C. coli, Shigella, and STEC. In some embodiments, a
plurality of
oligonucleotides, such as a plurality of primer pairs or a plurality of primer
pairs and third
oligonucleotides that are optionally labeled (e.g., for use as probes), are
configured to
collectively hybridize to one or more target nucleic acids of one or more
enteric pathogens,
including Salmonella, C. .guni, C. coli, Shigella, or STEC.
[00153] In some embodiments, one or more oligonucleotides comprise a non-
Watson
Crick (NWC) position. In some embodiments, a Salmonella primer, a Salmonella
primer pair,
46
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
and/or a Salmonella probe comprises a NWC position, such as a position that
includes
inosine. In some embodiments, a C. jg.uni primer, a C. jg.uni primer pair,
and/or a C. jg.uni
probe comprises a NWC position, such as a position that includes inosine. In
some
embodiments, a C. coli primer, a C. cob primer pair, and/or a C. cob probe
comprises a NWC
position, such as a position that includes inosine. In some embodiments, a
Shigella primer, a
Shigella primer pair, and/or a Shigella probe comprises a NWC position, such
as a position
that includes inosine. In some embodiments, a STEC primer, a STEC primer pair,
and/or a
STEC probe comprises a NWC position, such as a position that includes inosine.
[00154] In some embodiments, one or more oligonucleotides comprise a position
comprising 5-methylcytosine. In some embodiments, a Salmonella primer, a
Salmonella primer
pair, and/or a Salmonella probe comprises a position comprising 5-
methylcytosine. In some
embodiments, a C. .guni primer, a C. .guni primer pair, and/or a C. .guni
probe comprises a
position comprising 5-methylcytosine. In some embodiments, a C. co/i primer, a
C. cob
primer pair, and/or a C. cob probe comprises a position comprising 5-
methylcytosine. In
some embodiments, a Shigella primer, a Shigella primer pair, and/or a S
higella probe comprises
a position comprising 5-methylcytosine. In some embodiments, a STEC primer, a
STEC
primer pair, and/or a STEC probe comprises a position comprising 5-
methylcytosine.
[00155] In some embodiments, the first and second oligomers of the Salmonella-
specific
amplification oligomer set respectively comprise target-hybridizing sequences
comprising
SEQ ID NO:12 and SEQ ID NO: 14. In some embodiments, the first and second
oligomers of the Salmonella-specific amplification oligomer set respectively
comprise target-
hybridizing sequences comprising SEQ ID NO:21 and SEQ ID NO:47. In some
embodiments, the first and second oligomers of the Salmonella-specific
amplification
oligomer set respectively comprise target-hybridizing sequences comprising SEQ
ID NO:38
and SEQ ID NO:36. In some embodiments, the first and second oligomers of the
Salmonella-specific amplification oligomer set respectively comprise target-
hybridizing
sequences comprising SEQ ID NO:35 and SEQ ID NO:40. In some embodiments, the
first
and second oligomers of the Salmonella-specific amplification oligomer set
respectively
comprise target-hybridizing sequences comprising SEQ ID NO:12 and SEQ ID
NO:28. In
47
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
some embodiments, the first and second oligomers of the Salmonella-specific
amplification
oligomer set respectively comprise target-hybridizing sequences comprising SEQ
ID NO:42
and SEQ ID NO:31. In some embodiments, the first and second oligomers of the
Salmonella-specific amplification oligomer set respectively comprise target-
hybridizing
sequences comprising SEQ ID NO:41 and SEQ ID NO:27.
[00156] In some embodiments, the first and second oligomers of the C. jgnni-
specific
amplification oligomer set respectively comprise target-hybridizing sequences
comprising
SEQ ID NO:11 and SEQ ID NO:19.
[00157] In some embodiments, the first and second oligomers of the C. jgnni-
specific
amplification oligomer set respectively consist of target-hybridizing
sequences comprising
SEQ ID NO:11 and SEQ ID NO:19.
[00158] In some embodiments, the first and second oligomers of the C. co/i-
specific
amplification oligomer set respectively comprise target-hybridizing sequences
comprising
SEQ ID NO:8 and SEQ ID NO:10.
[00159] In some embodiments, the first and second oligomers of the C. co/i-
specific
amplification oligomer set respectively consist of target-hybridizing
sequences comprising
SEQ ID NO:8 and SEQ ID NO:10.
[00160] In some embodiments, the first and second oligomers of the Shigella-
specific
amplification oligomer set respectively comprise target-hybridizing sequences
comprising
SEQ ID NO:15 and SEQ ID NO:17. In some embodiments, the first and second
oligomers
of the Shigeila-specific amplification oligomer set respectively comprise
target-hybridizing
sequences comprising SEQ ID NO:34 and SEQ ID NO:22. In some embodiments, the
first
and second oligomers of the Shigella-specific amplification oligomer set
respectively comprise
target-hybridizing sequences comprising SEQ ID NO:32 and SEQ ID NO:33.
[00161] In some embodiments, the first and second oligomers of the Shigella-
specific
amplification oligomer set respectively consist of target-hybridizing
sequences comprising
SEQ ID NO:15 and SEQ ID NO:17. In some embodiments, the first and second
oligomers
of the Shigeila-specific amplification oligomer set respectively consist of
target-hybridizing
sequences comprising SEQ ID NO:34 and SEQ ID NO:22. In some embodiments, the
first
48
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
and second oligomers of the Shigella-specific amplification oligomer set
respectively consist
of target-hybridizing sequences comprising SEQ ID NO:32 and SEQ ID NO:33.
[00162] In some embodiments, the first and second oligomers of the STEC-
specific
amplification oligomer set respectively comprise target-hybridizing sequences
comprising
SEQ ID NO:20 and SEQ ID NO:3. In some embodiments, the first and second
oligomers
of the STEC-specific amplification oligomer set respectively comprise target-
hybridizing
sequences comprising SEQ ID NO:49 and SEQ ID NO:3. In some embodiments, the
first
and second oligomers of the STEC-specific amplification oligomer set
respectively comprise
target-hybridizing sequences comprising SEQ ID NO:4 and SEQ ID NO:7.
[00163] In some embodiments, the first and second oligomers of the STEC-
specific
amplification oligomer set respectively consist of target-hybridizing
sequences comprising
SEQ ID NO:20 and SEQ ID NO:3. In some embodiments, the first and second
oligomers
of the STEC-specific amplification oligomer set respectively consist of target-
hybridizing
sequences comprising SEQ ID NO:49 and SEQ ID NO:3. In some embodiments, the
first
and second oligomers of the STEC-specific amplification oligomer set
respectively consist of
target-hybridizing sequences comprising SEQ ID NO:4 and SEQ ID NO:7.
[00164] Exemplary primer pairs and optional third oligomers (e.g., probe) are
set forth in
the following Table A.
49
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[00165] Table A. Exemplary oligonucleotide sets. Oligonucleotides are referred
to by their
SEQ ID NO (see the Sequence Table below).
Oligonucleotide 1 Oligonucleotide 2 Oligonucleotide
3
(e.g., forward primer) (e.g., reverse primer) (e.g., probe; optionally
labeled)
Salmonella
12 14 13
21 47 45
38 36 44, 26, or 25
35 40 30
12 28 13
42 31 23
41 27 43
C. jejuni
11 19 18
C. co/i
8 10 9, 37, or 39
Shigella
15 17 16
34 22 46 or 29
32 33 24
STEC
20 3 1, 2, or 48
49 3 1, 2, or 48
4 7 5 or 6
[00166] In some embodiments, an oligonucleotide is provided that comprises a
label. Such
an oligonucleotide can be used as a probe. In some embodiments, the labeled
oligonucleotide has a sequence corresponding to a SEQ ID NO listed in the
Oligomer 3
column of Table A. In some embodiments, the label is a non-nucleotide label.
Suitable
labels include compounds that emit a detectable light signal, e.g.,
fluorophores or
luminescent (e.g., chemiluminescent) compounds that can be detected in a
homogeneous
mixture. More than one label, and more than one type of label, may be present
on a
particular probe, or detection may rely on using a mixture of probes, in which
each probe is
labeled with a compound that produces a detectable signal (see. e.g., US Pat.
Nos. 6,180,340
and 6,350,579, each incorporated by reference herein). Labels may be attached
to a probe by
various means including covalent linkages, chelation, and ionic interactions,
but in some
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
embodiments the label is covalently attached. For example, in some
embodiments, a
detection probe has an attached chemiluminescent label such as, e.g., an
acridinium ester
(AE) compound (see, e.g., US Pat. Nos. 5,185,439; 5,639,604; 5,585,481; and
5,656,744). A
label, such as a fluorescent or chemiluminescent label, can be attached to the
probe by a
non-nucleotide linker (c Pat. Nos. 5,585,481; 5,656,744; and 5,639,604). In
some
embodiments, the label may include one or more of Quasar670, CalRed610,
CalOrange560,
fluorescein, ROX, FAM, and HEX.
[00167] In some embodiments, a probe (e.g., comprising a fluorescent label)
further
comprises a second label that interacts with the first label. For example, the
second label can
be a quencher. In some embodiments, the second label may include one or both
of BHQ-1
and BHQ-2.Such probes can be used, e.g., in TaqManTm assays, where
hybridization of the
probe to a target or amplicon followed by nucleolysis by a polymerase
comprising 5'-3'
exonuclease activity results in liberation of the fluorescent label and
thereby increased
fluorescence, or fluorescence independent of the interaction with the second
label.
[00168] In some applications, one or more probes exhibiting at least some
degree of self-
complementarity are used to facilitate detection of probe:target duplexes in a
test sample
without first requiring the removal of unhybridized probe prior to detection.
Specific
embodiments of such detection probes include, for example, probes that form
conformations held by intramolecular hybridization, such as conformations
generally
referred to as hairpins. Suitable hairpin probes include a "molecular torch"
(see, e.g., US Pat.
Nos. 6,849,412; 6,835,542; 6,534,274; and 6,361,945) and a "molecular beacon"
(see, e.g., US
Pat. No. 5,118,801 and U.S. Pat. No. 5,312,728). Molecular torches include
distinct regions
of self-complementarity (coined "the target binding domain" and "the target
closing
domain") which are connected by a joining region (e.g., a -(CH2CH20) 3-
linker) and which
hybridize to one another under predetermined hybridization assay conditions.
When
exposed to an appropriate target or denaturing conditions, the two
complementary regions
(which may be fully or partially complementary) of the molecular torch melt,
leaving the
target binding domain available for hybridization to a target sequence when
the
predetermined hybridization assay conditions are restored. Molecular torches
are designed so
51
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
that the target binding domain favors hybridization to the target sequence
over the target
closing domain. The target binding domain and the target closing domain of a
molecular
torch include interacting labels (e.g., fluorescent/quencher) positioned so
that a different
signal is produced when the molecular torch is self-hybridized as opposed to
when the
molecular torch is hybridized to a target nucleic acid, thereby permitting
detection of
probe:target duplexes in a test sample in the presence of unhybridized probe
having a viable
label associated therewith.
[00169] Examples of interacting donor/acceptor label pairs that may be used in
connection
with the disclosure, making no attempt to distinguish FRET from non-FRET
pairs, include
fluorescein/tetramethylrhodamine, IAEDANS/fluororescein, EDANS/DABCYL,
coumarin/DABCYL, fluorescein/fluorescein, BODIPY FL/BODIPY FL,
fluorescein/DABCYL, lucifer yellow/DABCYL, BODIPY/DABCYL, eosine/DABCYL,
erythrosine/DABCYL, tetramethylrhodamine/DABCYL, Texas Red/DABCYL,
CY5/BHQ-1, CY5/BHQ-2, CY3/BHQ-1, CY3/BHQ-2 and fluorescein/QSY7 dye. Those
having an ordinary level of skill in the art will understand that when donor
and acceptor dyes
are different, energy transfer can be detected by the appearance of sensitized
fluorescence of
the acceptor or by quenching of donor fluorescence. Non-fluorescent acceptors
such as
DABCYL and the QSY7 dyes advantageously eliminate the potential problem of
background fluorescence resulting from direct (i.e., non-sensitized) acceptor
excitation.
Exemplary fluorophore moieties that can be used as one member of a donor-
acceptor pair
include fluorescein, ROX, and the CY dyes (such as CY5). Exemplary quencher
moieties
that can be used as another member of a donor-acceptor pair include DABCYL and
the
Black Hole Quencher moieties which are available from Biosearch Technologies,
Inc.,
(Novato, Calif.).
[00170] In some embodiments, a labeled oligonucleo tide (e.g., probe) is non-
extendable.
For example, the labeled oligomer can be rendered non-extendable by 3'-
phosphorylation,
having a 3'-terminal 3'-deoxynucleotide (e.g., a terminal 2',3'-
dideoxynucleotide), having a 3'-
terminal inverted nucleotide (e.g., in which the last nucleotide is inverted
such that it is
joined to the penultimate nucleotide by a 3' to 3' phosphodiester linkage or
analog thereof,
52
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
such as a phosphorothioate), or having an attached fluorophore, quencher, or
other label
that interferes with extension (possibly but not necessarily attached via the
3' position of the
terminal nucleotide). In some embodiments, the 3'-terminal nucleotide is not
methylated.
[00171] Also provided by the disclosure is a reaction mixture for determining
the presence
or absence of a target nucleic acid of at least one enteric pathogen, such as
Salmonella, C.
jg.uni, C. coli, Shigella, and STEC, or quantifying the amount thereof in a
sample. A reaction
mixture in accordance with the present disclosure comprises at least one or
more of the
following: an oligonucleotide as described herein for amplification of a
target nucleic acid;
and an oligonucleotide (e.g., probe) as described herein for determining the
presence or
absence of an amplification product of the target nucleic acid. For a reaction
mixture that
includes a detection probe together with an amplification oligonucleotide
combination, the
amplification oligonucleotides and detection probe oligonucleotides for a
reaction mixture
are linked by a common target region (i.e., the reaction mixture will include
a probe that
binds to a sequence amplifiable by an amplification oligonucleotides
combination of the
reaction mixture).
[00172] The reaction mixture may further include a number of optional
components such
as, for example, capture probes, e.g., poly-(k) capture probes as described in
US
2013/0209992, which is incorporated herein by reference, and/or poly-(R)
capture probes as
described in US 2020/0165599, which is incorporated herein by reference. For
an
amplification reaction mixture, the reaction mixture will typically include
other reagents
suitable for performing in vitro amplification such as, e.g., buffers, salt
solutions, appropriate
nucleotide triphosphates (e.g., dATP, dCTP, dGTP, and dTTP; and/or ATP, CTP,
GTP and
UTP), and/or enzymes (e.g., a thermostable DNA polymerase, or reverse
transcriptase
and/or RNA polymerase), and will typically include test sample components, in
which a
target nucleic acid may or may not be present. Suitable reagents include, for
example,
formulations containing lithium lauryl sulfate (LLS), sodium lauryl sulfate
(SLS), NaH2PO4,
Na2HPO4, EDTA, EGTA, Li0H, NaCl, KC1, MgCl2, NaOH, ethanol, methylparaben,
propylparaben, trehalose, Tris Buffer, Triton X-100, paramagnetic particles,
target capture
53
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
oligonucleotides, HEPES, succinic acid, polymerases (e.g., DNA polymerases,
reverse
transcriptases), and/or RNasin.
[00173] In some embodiments, the reaction mixture comprises KC1. In some
embodiments, the KC1 concentration is about 50 mM. In some embodiments, the
KC1
concentration is greater than about 50 m1\4, e.g., about 60-150 mM, about 75-
125 mM, about
80-120 m1\4, about 85-115 mM, or about 90-110 mM. In some embodiments, the KC1
concentration is 55-65, 65-75, 75-85, 85-95, 95-105, 105-115, 115-125, 125-
135, or 135-145,
wherein each of the foregoing is in mM and is optionally modified by "about".
In some
embodiments, a composition according to the disclosure comprises KC1, e.g., at
any of the
foregoing concentrations. In some embodiments, a method according to the
disclosure
comprises performing an amplification reaction in the presence of KC1, e.g.,
at any of the
foregoing concentrations.
[00174] In some embodiments, the reaction mixture comprises a-cyclodextrin
and/or
polysorbate 20. In some embodiments, the concentration of a-cyclodextrin in
the reaction
mixture is from about 10 mg/mL to about 40 mg/mL. In some embodiments, the
concentration of a-cyclodextrin in the reaction mixture is from about 16 mg/mL
to about 30
mg/mL, from about 15 mg/mL to about 20 mg/mL, or from about 10 mg/mL to about
15
mg/mL. In some embodiments, the concentration of a-cyclodextrin in the
reaction mixture
is about 20 mg/mL, about 17.5 mg/mL, or about 12.5 mg/mL. In some embodiments,
the
concentration of polysorbate 20 in the reaction mixture is from about 0.002%
to about
0.05% (v/v). In some embodiments, the concentration of polysorbate 20 in the
reaction
mixture is from about 0.003% to about 0.03% (v/v). In some embodiments, the
concentration of polysorbate 20 in the reaction mixture is about 0.0042%
(v/v), about
0.0035% (v/v), about 0.0026% (v/v), or about 0.02% (v/v). In some embodiments,
the
reaction mixture comprises a detergent. In some embodiments, the detergent
comprises
sodium dodecyl sulfate. In some embodiments, the concentration of the
detergent in the
reaction mixture is from about 3 mg/mL to 300 mg/mL. In some embodiments, the
concentration of the detergent in the reaction mixture is from about 10 mg/mL
to 100
54
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
mg/mL. In some embodiments, the concentration of the detergent in the reaction
mixture is
about 33.3 mg/mL.
[00175] Also provided by the subject disclosure are kits for practicing the
methods as
described herein. A kit in accordance with the present disclosure comprises at
least one or
more of the following: an oligonucleotide as described herein for
amplification of a target
nucleic acid; and an oligonucleotide (e.g., probe) as described herein for
determining the
presence or absence of an amplification product of the target nucleic acid. In
some
embodiments, any oligonucleotide combination described herein is present in
the kit. The
kits may further include a number of optional components such as, for example,
capture
probes, e.g., poly-(k) capture probes as described in US 2013/0209992 and/or
poly-(R)
capture probes as described in US 2020/0165599. Other reagents that may be
present in the
kits include reagents suitable for performing in vitro amplification such as,
e.g., buffers, salt
solutions, appropriate nucleotide triphosphates (e.g., dATP, dCTP, dGTP, dTTP;
and/or
ATP, CTP, GTP and UTP), and/or enzymes (e.g., a thermostable DNA polymerase,
or a
reverse transcriptase and/or RNA polymerase). Oligonucleo tides as described
herein may be
packaged in a variety of different embodiments, and those skilled in the art
will appreciate
that the disclosure embraces many different kit configurations. For example, a
kit may
include amplification oligonucleotides for only one, two, three, four, or all
of Salmonella, C.
jg.uni, C. coli, Shigella, and STEC. In addition, for a kit that includes a
detection probe together
with an amplification oligomer combination, the amplification oligonucleotides
and
detection probe oligonucleotides for a reaction mixture are linked by a common
target
region (i.e., the reaction mixture will include a probe that binds to a
sequence amplifiable by
an amplification oligonucleotides combination of the reaction mixture). In
certain
embodiments, the kit further includes a set of instructions for practicing
methods in
accordance with the present disclosure, where the instructions may be
associated with a
package insert and/or the packaging of the kit or the components thereof.
[00176] Also provided by the subject disclosure are methods (e.g., multiplex
methods) for
determining the presence or absence of at least one enteric pathogen,
including Salmonella, C.
jg.uni, C. coli, Shigella, and STEC, in a sample by, for example, using one or
more of the
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
oligonucleotides disclosed herein. Any method disclosed herein is also to be
understood as a
disclosure of corresponding uses of materials involved in the method directed
to the purpose
of the method. Any of the oligonucleotides and any combinations (e.g., kits
and
compositions) comprising such an oligonucleotide are to be understood as also
disclosed for
use in detecting or quantifying at least one enteric pathogen, and for use in
the preparation
of a composition for detecting or quantifying at least one enteric pathogen.
[00177] Broadly speaking, methods can comprise one or more of the following
components: target capture, in which a target nucleic acid (e.g., from a
sample, such as a
clinical sample) is annealed to a capture oligonucleotide; isolation, e.g.,
washing, to remove
material not associated with a capture oligonucleotide; amplification; and
amplicon
detection, e.g., amplicon quantification, which may be performed in real time
with
amplification. Certain embodiments involve each of the foregoing steps.
Certain
embodiments involve exponential amplification, optionally with a preceding
linear
amplification step. Certain embodiments involve exponential amplification and
amplicon
detection. Certain embodiments involve any two of the components listed above.
Certain
embodiments involve any two components listed adjacently above, e.g., washing
and
amplification, or amplification and detection.
[00178] In some embodiments, amplification comprises (1) contacting the sample
with at
least two oligonucleotides for amplifying a target nucleic acid target region
corresponding to
a target nucleic acid, where the oligonucleotides include at least two
amplification
oligonucleotides as described above (e.g., one or more oriented in the sense
direction and
one or more oriented in the antisense direction for exponential
amplification);
(2) performing an in vitro nucleic acid amplification reaction, where any
target nucleic acid
present in the sample is used as a template for generating an amplification
product; and
(3) detecting the presence or absence of the amplification product, thereby
determining the
presence or absence of at least one enteric pathogen, including Salmonella, C.
jg.uni, C. coli,
Shigella, and STEC, in a sample, or quantifying the amount of the target
nucleic acid in the
sample.
56
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[00179] A detection method in accordance with the present disclosure can
further include
the step of obtaining the sample to be subjected to subsequent steps of the
method. In
certain embodiments, "obtaining" a sample to be used includes, for example,
receiving the
sample at a testing facility or other location where one or more steps of the
method are
performed, and/or retrieving the sample from a location (e.g., from storage or
other
depository) within a facility where one or more steps of the method are
performed.
[00180] In certain embodiments, the method further includes purifying the
target nucleic
acid from other components in the sample, e.g., before an amplification, such
as before a
capture step. Such purification may include methods of separating and/or
concentrating
organisms contained in a sample from other sample components, or removing or
degrading
non-nucleic acid sample components, e.g., protein, carbohydrate, salt, lipid,
etc. In some
embodiments, nucleic acid in the sample is degraded, e.g., with DNase, and
optionally
removing or inactivating the DNase or removing degraded nucleic acid.
[00181] In particular embodiments, purifying the target nucleic acid includes
capturing the
target nucleic acid to specifically or non-specifically separate the target
nucleic acid from
other sample components. Non-specific target capture methods may involve
selective
precipitation of nucleic acids from a substantially aqueous mixture, adherence
of nucleic
acids to a support that is washed to remove other sample components, or other
means of
physically separating nucleic acids from a mixture that contains the target
nucleic acid and
other sample components.
[00182] Target capture typically occurs in a solution phase mixture that
contains one or
more capture probe oligonucleotide that hybridize to the target nucleic acid
sequence under
hybridizing conditions. For embodiments comprising a capture probe tail, the
target:capture-
probe complex is captured by adjusting the hybridization conditions so that
the capture
probe tail hybridizes to the immobilized probe. Certain embodiments use a
particulate solid
support, such as paramagnetic beads.
[00183] Isolation can follow capture, wherein the complex on the solid support
is separated
from other sample components. Isolation can be accomplished by any apporpiate
technique,
e.g., washing a support associated with the target-sequence one or more times
(e.g., 2 or 3
57
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
times) to remove other sample components and/or unbound oligomer. In
embodiments
using a particulate solid support, such as paramagnetic beads, particles
associated with the
target may be suspended in a washing solution and retrieved from the washing
solution, In
some embodiments by using magnetic attraction. To limit the number of handling
steps, the
target nucleic acid may be amplified by simply mixing the target sequence in
the complex on
the support with amplification oligomers and proceeding with amplification
steps.
[00184] Exponentially amplifying a target sequence utilizes an in vitro
amplification reaction
using at least two amplification oligonucleotides that flank a target region
to be amplified. In
some embodiments, at least one oligonucleotide as described above is provided.
In some
embodiments, a plurality of pairs of oligonucleotides is provided, wherein the
plurality
comprises oligonucleotides pairs configured to hybridize to at least one, two,
three, four, or
all of Salmonella, C..guni, C. coli, S higella, and STEC target nucleic acids.
The amplification
reaction can be cycled or isothermal. Suitable amplification methods include,
for example,
replicase-mediated amplification, polymerase chain reaction (PCR), ligase
chain reaction
(LCR), strand-displacement amplification (SDA), and transcription-mediated or
transcription-associated amplification (TMA).
[00185] A detection step may be performed using any of a variety of known
techniques to
detect a signal specifically associated with the amplified target sequence,
such as, e.g., by
hybridizing the amplification product with a labeled detection probe and
detecting a signal
resulting from the labeled probe (including from label released from the probe
following
hybridization in some embodiments), performing electrophoresis on the sample
and/or the
amplification product, determining the sequence of the amplification product.
In some
embodiments, the labeled probe comprises a second moiety, such as a quencher
or other
moiety that interacts with the first label, as discussed above. The detection
step may also
provide additional information on the amplified sequence, such as, e.g., all
or a portion of its
nucleic acid base sequence. Detection may be performed after the amplification
reaction is
completed, or may be performed simultaneously with amplifying the target
region, e.g., in
real time. In one embodiment, the detection step allows homogeneous detection,
e.g.,
detection of the hybridized probe without removal of unhybridized probe from
the mixture
58
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
(see, e.g., US Pat. Nos. 5,639,604 and 5,283,174). In some embodiments, the
nucleic acids are
associated with a surface that results in a physical change, such as a
detectable electrical
change. Amplified nucleic acids may be detected by concentrating them in or on
a matrix
and detecting the nucleic acids or dyes associated with them (e.g., an
intercalating agent such
as ethidium bromide or cyber green), or detecting an increase in dye
associated with nucleic
acid in solution phase. Other methods of detection may use nucleic acid
detection probes
that are configured to specifically hybridize to a sequence in the amplified
product and
detecting the presence of the probe:product complex, or by using a complex of
probes that
may amplify the detectable signal associated with the amplified products (see,
e.g., US Pat.
Nos. 5,424,413; 5,451,503; and 5,849,481; each incorporated by reference
herein). Directly or
indirectly labeled probes that specifically associate with the amplified
product provide a
detectable signal that indicates the presence of the target nucleic acid in
the sample. In
particular, the amplified product will contain a target sequence in or
complementary to a
target nucleic sequence of at least one enteric pathogen, and a probe will
bind directly or
indirectly to a sequence contained in the amplified product to indicate the
presence or
absence of the pathogen in the tested sample.
[00186] In embodiments that detect the amplified product near or at the end of
the
amplification step, a linear detection probe may be used to provide a signal
to indicate
hybridization of the probe to the amplified product. One example of such
detection uses a
luminescentally labeled probe that hybridizes to target nucleic acid.
Luminescent label is then
hydrolyzed from non-hybridized probe. Detection is performed by
chemiluminescence using
a luminometer (see, e.g., PCT Pub. No. WO 89/002476). In other embodiments
that use real-
time detection, the detection probe may be a hairpin probe such as, for
example, a molecular
beacon, molecular torch, or hybridization switch probe that is labeled with a
reporter moiety
that is detected when the probe binds to amplified product. Such probes may
comprise
target-hybridizing sequences and non-target-hybridizing sequences. Various
forms of such
probes are described, e.g., in U.S. Pat. Nos. 5,118,801; 5,312,728; 5,925,517;
6,150,097;
6,849,412; 6,835,542; 6,534,274; and 6,361,945; and US Pub. Nos.
2006/0068417A1 and
2006/0194240A1).
59
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[00187] In some embodiments, in an amplication reaction, an amplification
oligonucleotide
may preferentially hybridize with a target nucleic acid, such as a target
sequence of a
pathogen. In some embodiments, in a detection step, a probe may preferentially
hybridize
with a target nucleic acid, such as an amplification product. For example,
under stringent
hybridization conditions, an amplification or detection probe oligonucleotide
can hybridize
to its target nucleic acid to form stable oligonucleotide:target hybrids, but
not form a
sufficient number of stable oligonucleotide:non-target hybrids. In some
embodiments, there
is at least a 5-fold difference between target and non-target hybridization
signals (i.e., the
ratio of signal strengths of oligonucleotide:target hybrids and of
oligonucleotide:non-target
hybrids) in a test sample, at least a 10-fold difference, at least a 20-fold
difference, at least a
50-fold difference, at least a 75-fold difference, at least a 100-fold
difference, at least a 200-
fold difference, at least a 500-fold difference, at least a 1,000-fold
difference, or at least a
2,000-fold difference. In some embodiments, non-target hybridization signals
in a test
sample are no more than the background signal level.
[00188] In some embodiments, an amplification reaction and/or a detection step
may be
performed under stringent hybridization conditions. In some embodiments, such
stringent
hybridization conditions permit an oligonucleotide (e.g., an amplification
oligonucleotide or
probe) to preferentially hybridize to a target nucleic acid (such as a target
sequence of a
pathogen or an amplification product) and not to nucleic acid derived from a
closely related
non-target nucleic acid. In different embodiments, the actual reaction
environment that can
be used for stringent hybridization may vary depending upon factors including
the GC
content and length of the oligonucleotide, the degree of similarity between
the
oligonucleotide sequence and sequences of non-target nucleic acids that may be
present in
the test sample, and the target sequence. In some embodiments, hybridization
conditions for
an amplification reaction and/or a detection step correspond to a temperature
of about
55 C, about 56 C, about 57 C, about 58 C, about 59 C, about 60 C, about
61 C, about
62 C, about 63 C, about 64 C, or about 65 C when the salt concentration,
such as a
monovalent salt, e.g., KC1, is about 0.5 M, about 0.6 M, about 0.7 M, about
0.8 M, about 0.9
M, or about 1.0 M.
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[00189] The methods (e.g., multiplex methods) for determining the presence or
absence of
at least one enteric pathogen, including Salmonella, C. jg.uni, C. coli,
Shigella, and STEC, in a
sample by, for example, using one or more of the oligonucleotides disclosed
herein may have
a detection sensitivity from 25 to 500 CFU/mL, from 50 to 500 CFU/mL, from 75
to 500
CFU/mL, from 100 to 500 CFU/mL, from 25 to 300 CFU/mL, from 50 to 300 CFU/mL,
from 75 to 300 CFU/mL, from 100 to 300 CFU/mL, from 25 to 150 CFU/mL, from 50
to
150 CFU/mL, from 75 to 150 CFU/mL, from 100 to 150 CFU/mL, from 25 to 100
CFU/mL, from 50 to 100 CFU/mL, from 75 to 100 CFU/mL, from 25 to 75 CFU/mL,
from 50 to 75 CFU/mL, or from 25 to 50 CFU/mL.
[00190] Also provided by the subject disclosure are methods for synthesizing
one or more
(e.g., one or more pairs) of the oligonucleotides disclosed herein, the
oligonucleotides useful
for determining the presence or absence of at least one enteric pathogen,
including
Salmonella, C. .guni, C. coli, Shigella, and STEC. The method may, for
example, include the
steps of (a) obtaining a solid support comprising at least one nucleobase
residue, wherein the
at least one nucleobase residue is bound (e.g., covalently bound) at a 3'
position to the solid
support; (b) coupling a 5' position of the nucleobase residue fur therest from
the solid
support to a 3' position of another nucleobase residue; (c) repeating step (b)
at least 10, at
least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at
least 17, at least 18, at
least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at
least 25, at least 26, at
least 27, or at least 28 additional times, thereby generating at least 12, at
least 13, at least 14,
at least 15, at least 16, at least 17, at least 18, at least 19, at least 20,
at least 21, at least 22, at
least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at
least 29, or at least 30
contiguous nucleobase residues coupled to the solid support; and (d) cleaving
the at least 12,
at least 13, at least 14, at least 15, at least 16, at least 17, at least 18,
at least 19, at least 20, at
least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at
least 27, at least 28, at
least 29, or at least 30 contiguous nucleobase residues generated in step (c),
thereby
obtaining the oligonucleotide or oligonucleotides. In some embodiments, the
oligonucleotide has a length of from 18 to 32 contiguous nucleobase residues.
In some
61
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
embodiments, the oligonucleotide has a length of from 20 to 30 contiguous
nucleobase
residues.
[00191] A method for synthesizing one or more of the oligonucleotides
disclosed herein
may be a solid phase method. For example, phosphoramidite solid-phase
chemistry for
joining nucleotides by phosphodiester linkages is disclosed in Caruthers et
al., "Chemical
Synthesis of Deoxynucleotides by the Phosphoramidite Method," Methods Enumol.
154:287
(1987). As another example, automated solid-phase chemical synthesis using
cyanoethyl
phosphoramidite precursors has been described in Barone et al., "In Situ
Activation of bis-
dialkylaminephosphines ¨ a New Method for Synthesizing Deoxyoligonucleotides
on
Polymer Supports," Nucleic Acids Res. 12(10):4051 (1984). As another example,
US Patent
No. 5,449,769, entitled "Method and Reagent for Sulfurization of
Organophosphorous
Compounds" discloses a procedure for synthesizing oligonucleotides containing
phosphorothioate linkages. In addition, US Patent No. 5,811,538, entitled
"Process for the
Purification of Oligomers" discloses the synthesis of oligonucleotides having
different
linkages, including methylphosphonate linkages. Moreover, methods for the
organic
synthesis of oligonucleotides are described in, for example, Sambrook et al.,
Molecular Cloning,
A Laboratog Manual, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring
Harbor,
NY, 1989) at Chapt. 10.
[00192] Following synthesis and purification of a particular oligonucleotide,
several
different procedures may be utilized to purify and control the quality of the
oligonucleotide.
Suitable procedures include electrophoresis (e.g., polyacrylamide gel
electrophoresis) or
chromatography (e.g, high pressure liquid chromatography).
EXAMPLES
[00193] The following examples are provided to illustrate certain disclosed
embodiments
and are not to be construed as limiting the scope of this disclosure in any
way.
62
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
Example 1 ¨ Real-Time PCR Amplification and Detection of GI-Bacterial Panel
Targets Using Different Combinations of Primers and Probes
[00194] Several primer and probe combinations for real-time PCR amplification
and
detection of Salmonella, Campylobacter, Shigella /Enteroinvasive E. coli
(Shigella/EIEC), and
Shigatoxigenic E. coli (STEC) targets were tested.
[00195] Amplification and detection reactions were performed using a Panther
Fusion
instrument (Hologic, Inc. San Diego, CA). Typically, 20111- of an
amplification reagent was
combined in a reaction well of a multi-well plate with 5111- of a target
nucleic acid. The
multi-well plate was placed in the Panther Fusion instrument and subjected to
thermal
cycling. Real-time amplification and detection reactions were performed by
thermal cycling,
generally for 45 cycles (denaturation at 95 C for 8 seconds and annealing and
extension at
60 C for 25 seconds), taking fluorescent emission readings every 30 seconds.
Fluorescence
curve profiles for the target nucleic acids were evaluated for Ct and RFU
signals.
Example 2 ¨ Analytical Sensitivity-Bacterial Limit of Detection
[00196] Analytical sensitivity experiments were performed for determining the
limit of
detection (LoD) for target nucleic acids of six individual bacterial
organisms, using a
multiplex primer-probe combination. The primers and probes used in the
experiment are
shown in Table 1. Known stock concentrations of each organism (available from
American
Type Tissue Culture, Manassas, VA) were serially diluted in a raw stool matrix
to provide a
series of 5 dilution concentrations for each organism. Salmonella ophimurium,
Campylobacter coli,
Campylobacterjg.uni, Shigella sonnei, Shiga Toxin-producing Escherichia coli
0157:H7 (STEC stx1
and STEC stx2) were each serially diluted to provide the following
concentrations: 1,000
CFU/mL, 500 CFU/mL, 300 CFU/mL, 150 CFU/mL, and 100 CFU/mL. Campylobacter
jg.uni was serially diluted to provide the following concentrations: 1,000
CFU/mL, 500
CFU/mL, 300 CFU/mL, 100 CFU/mL, and 75 CFU/mL. Each of the dilutions was
tested
in replicates of 5, and Ct and RFU data are presented in Table 2. The lowest
concentration
that was 100 /0 positive for each organism was then further tested in
replicates of 20
(dilutions made in both raw stool matrix and Cary-Blair stool matrix), and the
Ct and RFU
data are presented in Table 3. Sample processing, target capture,
amplification and detection
63
CA 03226812 2024-01-15
WO 2023/010008
PCT/US2022/074151
reactions were generally performed as is described herein. An internal control
nucleic acid
was present in each amplification reaction.
[00197] Table 1. Primer-Probe Combinations
Oligo Type SEQ ID NO: Modifications*
SEQ ID NO:3
SEQ ID NO:4
SEQ ID NO:7 5mC at residues 3, 4, 18, and 19
SEQ ID NO:8
SEQ ID NO:10
SEQ ID NO:11
SEQ ID NO:12 5mC at residues 4, 11, 12, and 16
Primers
SEQ ID NO:14
Inosine at residue 3
SEQ ID NO:15
5mC at residues 7 and 15
SEQ ID NO:17
Inosine at residue 23
SEQ ID NO:19
5mC at residues 1,2, 7, 14, 15, 19, and 20
SEQ ID NO:20
5mC at residues 6, 7, 9, 14, 17, and 24
SEQ ID NO:1
Quasar670/BHQ2
5mC at residues 5, 8, 11, 13, 18, and 21
SEQ ID NO:2
Quasar670/BHQ2
SEQ ID NO:5 Quasar 670/BHQ2
5mC at residues 3, 7, 8, 15, 20, 24, and 27
SEQ ID NO:6
Probes Quasar670/BHQ2
5mC at residues 2, 6, 13, 16, 23, 26, 28, and 29
SEQ ID NO:9
BHQ1 /HEX
SEQ ID NO:13 BHQ1 /FAM
Inosine at residue 16
SEQ ID NO:16
CalRed610/BHQ2
5mC at residues 7 and 12
SEQ ID NO:18
HEX/BHQ1
* 5mC refers to a residue that comprises 5-methylcytosine. BHQ refers to Black
Hole
Quencher. FAM refers to fluorescein.
[00198] Table 2. Initial LoD Testing Results
Conc Avg
Signal
Target Reactivity Avg Ct Avg Total RFU Background to
(CFU/mL)
RFU
Noise
100 5/5 36.96 15,519 8,556 1.8
Salmonella
150 5/5 35.49 23,955 9,263 2.6
64
CA 03226812 2024-01-15
WO 2023/010008
PCT/US2022/074151
300 5/5 34.71 26,305 9,069 2.9
500 5/5 33.81 30,129 8,665 3.5
1,000 5/5 32.94 35,666 9,664 3.7
75 5/5 36.90 15,384 10,446 1.5
100 5/5 36.68 14,652 9,504 1.5
C. jg.uni 300 5/5 35.15 18,835 10,983 1.7
500 5/5 34.43 19,223 10,703 1.8
1,000 5/5 33.29 19,860 10,196 1.9
100 4/5 40.36 12,455 10,017 1.2
150 4/5 39.78 12,906 10,044 1.3
C. co/i 300 5/5 38.36 15,528 11,111 1.4
500 5/5 37.65 15,346 10,146 1.5
1,000 5/5 36.17 18,549 10,785 1.7
100 5/5 35.79 4,915 770 6.4
150 5/5 35.06 5,604 764 7.3
Shigella 300 5/5 34.34 6,791 782 8.7
500 5/5 33.49 7,568 771 9.8
1,000 5/5 32.58 8,775 820 10.7
100 5/5 38.31 6,971 4,952 1.4
150 5/5 38.82 6,287 4,380 1.4
STEC-
300 5/5 36.77 7,905 4,696 1.7
Six/
500 5/5 35.82 8,906 4,718 1.9
1,000 5/5 35.00 8,199 4,150 2.0
100 5/5 38.69 6,202 4,331 1.4
150 5/5 38.39 6,590 4,446 1.5
STEC-
300 5/5 36.94 7,152 4,351 1.6
Stx2
500 5/5 36.00 7,503 4,273 1.8
1,000 5/5 34.79 8,400 4,528 1.9
[00199] Table 3. Confirmatory LoD Testing Results
Avg Avg
Signal-
Conc Stool Avg
Target
Ct Total Background to-
Reactivity(CFU /mL) Matrix
RFU RFU
Noise
Raw 18/20 36.93 16,100 8,410 1.9
100 Gary-
19/20 36.12 18,638 8,839 2.1
Blair
Salmonella
Raw 19/20 36.64 13,089 9,338 1.4
150 Gary-
20/20 35.35 21,523 8,380 2.6
Blair
Raw 20/20 37.78 13,089 9,338 1.4
C. .guni 75 Cary-
20/20 36.30 20,001 10,962 1.8
Blair
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
Raw 20/20 40.57 12,987 10,285 1.3
150 Caw-
20/20 39.41 14,161 10,529 1.3
Blair
C. co/i
Raw 20/20 38.77 14,178 10,311 1.4
300 Caw-
20/20 37.63 16,193 10,553 1.5
Blair
Raw 20/20 35.97 5,049 838 6.0
Shigella 100 Caw-
20/20 35.43 5,618 867 6.5
Blair
STEC-
Raw 20/20 38.83 6,513 4,667 1.4
100 Ca 20/20 20/20 38.72 7,065 4,874 1.4
Blair
STEC-
Raw 20/20 38.99 6,465 4,561 1.4
100 Caw-
Stx2 20/20 38.32 7,153 4,890 1.5
Blair
[00200] Data from this experiment showed 100% positivity (5/5) at
concentrations at least
as low as 100 CFU/mL for Salmonella ophimurium, Shigella sonnei, STEC stx1 and
STEC stx2.
Campylobacter coli was 100% positive at 300 CFU/mL and 80% positive (4/5) at
100
CFU/mL, and Campylobacterjghni was 100% positive at 75 CFU/mL. Confirmatory
testing
showed 100% positivity (20/20) for each of Campylobacter coli,
Campylobacterjgnni, Shigella
sonnei, STEC stx1 and STEC stx2 in two different stool matrices. Salmonella
ophimurium was
90% positive in the raw stool matrix and 95% positive in the Cary-Blair stool
matrix. These
data show that the multiplex primer/probe combination has a sensitivity
between 75 to 150
CFU/mL.
Example 3 ¨ Primer-Probe Combinations for
Amplification and Detection of Salmonella
[00201] Several primer and probe combinations were prepared and tested for
amplification
and detection of Salmonella enterica. Combinations are described in Table 4
below. These
primer-probe combinations were tested against three concentrations of a
serially diluted
stock concentration of Salmonella enterica. Dilutions were made into a sample
transport
reagent and the 500 CFU/mL, 150 CFU/mL, and 50 CFU/mL concentrations were
tested.
Negative reaction wells were sample transport media. Reaction conditions were
set up in
66
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
triplicate and real-time amplification and detection reactions were performed.
RFU and Ct
results are shown in Table 5.
[00202] Table 4. Primer and Probe Combinations
Primer-Probe
SEQ ID NO: Oligo Type Modifications & Labels*
Combo No.
5mC at residues 13, 17, and 24
SEQ ID NO:21 Forward Primer
Inosine at residues 14, and 23
5mC at residues 11, 16, and 17
SEQ ID NO:47 Reverse Primer
Combo 1 Inosine at residue 4
5mC at residues 3, 6, 8, and 17
SEQ ID NO:45 Taqman Probe Inosine at residues 10, 15,
and 19
FAM/BHQ1
5mC at residues 4, 6, 7, and 8
SEQ ID NO:38 Forward Primer
Inosine at residue 22
5mC at residues 2, 3, 4, 16, 18,
SEQ ID NO:36 Reverse Primer 19, and 22
Combo 2
Inosine at residue 7
5mC at residues 7, 9, 13, and 15
SEQ ID NO:44 Taqman Probe Inosine at residues 5, and
8FAM/BHQ1
5mC at residues 4, 6, 7, and 8
SEQ ID NO:38 Forward Primer
Inosine at residue 22
5mC at residues 2, 3, 4, 16, 18,
SEQ ID NO:36 Reverse Primer 19, and 22
Combo 3
Inosine at residues 5, and 8
5mC at residues 9, 18, and 23
SEQ ID NO:26 Taqman Probe Inosine at residue 6
FAM/BHQ1
SEQ ID NO:35 Forward Primer
5mC at residues 4, 13, 18, and 22
SEQ ID NO:40 Reverse Primer
Inosine at residues 16, and 19
Combo 4 5mC at residues 2, 4, 18, 19,
and
SEQ ID NO:30 Taqman Probe
Inosine at residues 14, and 23
FAM/BHQ1
SEQ ID NO:12 Forward Primer 5mC at residues 4, 11, 12, and
16
5mC at residues 2, 4, 12, 14, 15,
Combo 5 SEQ ID NO:28 Reverse Primer and 17,
Inosine at residue 18
SEQ ID NO:13 Taqman Probe FAM/BHQ1
Combo 6 SEQ ID NO:42 Forward Primer Inosine at 10 and 16
67
CA 03226812 2024-01-15
WO 2023/010008
PCT/US2022/074151
5mC at residues 6, 7, 8, 13, 23,
SEQ ID NO:31 Reverse Primer 24, and 26
Inosine at residue 20
5mC at residues 2, 5, 7, and 14
SEQ ID NO:23 Taqman Probe Inosine at residue 15
FAM/BHQ1
SEQ ID NO:41 Forward Primer
SEQ ID NO:27 Reverse Primer 5mC at residues at 6, 10, and
18
5mC at residues 2, 9, 12, 16, 17,
Combo 7
22, 23, and 26
SEQ ID NO:43 Taqman Probe
Inosine at residue 15
FAM/BHQ1
* 5mC refers to a residue that comprises 5-methylcytosine. BHQ refers to Black
Hole
Quencher. FAM refers to fluorescein.
[00203] Table 5. Results
Primer-Probe
Condition Avg RFU Avg Ct
Combo No.
STM only
S. enterica
17,608 38.31
50 CFU/mL
Combo 3 S. enterica
20,326 37.19
150 CFU/mL
S. enterica
24,900 36.12
500 CFU/mL
STM only 271
S. enterica
23,236 37.14
50 CFU/mL
Combo 4 S. enterica
25,402 36.30
150 CFU/mL
S. enterica
28,034 35.29
500 CFU/mL
STM only
S. enterica
20,353 38.97
50 CFU/mL
Combo 5 S. enterica
22,824 37.54
150 CFU/mL
S. enterica
26,103 35.14
500 CFU/mL
STM only 28
S. enterica
Combo 6 5,605 41.32
50 CFU/mL
S. enterica 19,624 38.48
68
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
150 CFU/mL
S. enterica
500 CFU/mL 23,292 36.93
STM only
S. enterica
50 CFU/mL 13,119 38.98
Combo 7 S. enterica
150 CFU/mL 16,774 38.80
S. enterica
500 CFU/mL 21,322 35.90
[00204] Primer and probe combinations 1 and 2 showed only negative results in
this
experiment, and thus the results are not presented in Table 5. Each of
combinations 3 to 7
showed robust RFU over background. Combinations 4 and 5 showed the most robust
RFUs
and fastest Cts in this experiment.
Example 4 ¨ Analytical Specificity and Interference
[00205] Analytical specificity for an exemplary multiplex assay for detecting
Salmonella,
Shigella, Campylobacter (C..guni and C. co/i, undifferentiated), and STEC (stx-
1 and stx-2
undifferentiated) was tested. The assay was run as a real-time, multiplex PCR
reaction
utilizing the primer and probe combination of Table 1 and cycling parameters.
[00206] Analytical specificity of the PCR assay was determined using a total
of 81
organisms divided into 17 panels as listed in Table 6 and Table 6.1. These 81
organisms are
commonly found in stool samples (organisms available from American Type Tissue
Culture,
Manassas, VA). The 17 panels of organisms were spiked into negative Cary-Blair
stool
matrices. The concentrations of the organisms were 1E6 CFU/mL in each test,
except for
Bifidobacterium adolescentis,Egglerthella lenta, and Peptostreptococcus micros
with concentration of
1E6 rRNA copies/mL, and Entamoeba histolytica with a concentration of 1E4
cells/mL.
Positive control was Salmonella enterica (strain V1796), Campylobacter coli
(strain RO 268),
Shigella flexneri (strain 24570), and STEC (strain CDC 1999-3302) spiked at 3X
LoD into
Cary-Blair stool matrices. Negative control was Cary-Blair stool matrix only.
Reactions were
run in triplicate. Reactivity or positivity was defined as an amplification
curve crossing the Ct
threshold for each channel. Any curve below this threshold was considered as
negative or
69
CA 03226812 2024-01-15
WO 2023/010008
PCT/US2022/074151
not reactive. Ct thresholds used were: FAM, 600; HEX, 1000; ROX, 500; Q670,
600; and
Q705, 1000. Results are presented in Table 7, Table 7.1, Table 8, and Table
8.1.
[00207] Table 6. Analytical Specificity Panel
Panel No. Organism
Abiotrophia defectivia
Acinetobacter baumannii
Acinetobacter
1 lwojfJIi
Aeromonas hydrophila
Alcabgenes faecalis
Anaerococcus /e/radius
Anaerococcus vagina/is
Acrcobacter butleri
2 Bacillus cereus
Bacteriodes fragilis
Bacteroides thetaiotaomicron
Bacteroides vulgatus
Bifiodobacterium adolescentis
Biliodobacterium longum
3 Campylobac/erfe/us
Campylobacter hyointestinalis
Campylobacter rectus
Campylobacter sputorum
Candida albicans
Citrobacter.freundii
4 Citrobacter koseri
Clostridium difficile
Clostridium perfringens
Clostridium ramosum
Clostridium sordelli
Clostridium tedium
Collinsella aerofaciens
Corynebacterium genitalium
Cronobacter sakaakii
Edwardsiella tarda
Egglerthella lenta
En/amoeba histolytica
6 Entercoccus faecalis
Enterobacter aerogenes
Enterobacter cloacae
Escherichia coli
7 Escherichia coli
CA 03226812 2024-01-15
WO 2023/010008
PCT/US2022/074151
Escherichia fergusonii
Escherichia hermanii
Escherichia vulneris
Gardnerella vagina/is
Helicobacter pylori
Klebsiella oNytoca
Klebsiella oaenae
8 Klebsiella pneumoniae
Lactobacillus acidophilus
Lactobacillus crispatus
Lactococcus lactis
Leptotrichia buccalis
Listeria grayi
Listeria monogtogenes
9
Megasphaeara elsdenii
Morganella morganii
Peptostreptococcus anaerobius
Peptostreptococcus micros
Photobacterium damselae
Plesiomonas shigelloides
Prevotella bivia
Prevotella melaninogenica
Proteus mirabilis
Proteus penneri
Proteus vulgaris
11 Providencia alcalifaciens
Providencia rettgeri
Providencia stuartii
Pseudomonas aeruginosa
Pseudomonas fluorescens
Serratia liquffaciens
12 Serratia marcescens
Staphylococcus aureus
Staphylococcus epidermidis
Stenotrophomonas maltophilia
Streptococcus anginosus
Streptococcus clysgalactiae
13 Yersinia bercovieri
Yersinia pseudotuberculosis
Yersinia rohdei
14 Campylobacter lari
Campylobacter upsaliensis
71
CA 03226812 2024-01-15
WO 2023/010008
PCT/US2022/074151
[00208] Table 6.1. Analytical Specificity Panel (EIEC)
Panel No. Organism
A Escherichia coli 0124
(EIEC 0124)
B Escherichia coli 029
(EIEC 029)
[00209] Table 7. Specificity Data
Reactivity
Panel
Salmonella Campylobacter Shigella STEC
Control 0/3 0/3 0/3 0/3
1 0/3 0/3 0/3 0/3
2 0/3 0/3 0/3 0/3
3 0/3 0/3 0/3 0/3
4 0/3 0/3 0/3 0/3
0/3 0/3 0/3 0/3
6 0/3 0/3 0/3 0/3
7 0/3 0/3 0/3 0/3
8 0/3 0/3 0/3 0/3
9 0/3 0/3 0/3 0/3
0/3 0/3 0/3 0/3
11 0/3 0/3 0/3 0/3
12 0/3 0/3 0/3 0/3
13 0/3 0/3 0/3 0/3
14 0/3 0/3 0/3 0/3
0/3 0/3 0/3 0/3
[00210] Table 7.1. Specificity Data (EIEC)
Reactivity
Panel
Salmonella Campylobacter She//a STEC
Control 0/3 0/3 0/3 0/3
A 0/3 0/3 3/3 0/3
B 0/3 0/3 3/3 0/3
[00211] Table 8. Interference Data
Panel Salmonella Campylobacter Shigella STEC
Reactivity Avg Ct Reactivity Avg Ct Reactivity Avg Ct Reactivity Avg Ct
Control 3/3 33.6 3/3 35.9 3/3 31.3 3/3
36.5
72
CA 03226812 2024-01-15
WO 2023/010008
PCT/US2022/074151
1 3/3 34.1 3/3 36.2 3/3 31.8 3/3
37.3
2 3/3 33.7 3/3 35.9 3/3 31.6 3/3
37.4
3 3/3 33.8 3/3 35.7 3/3 31.4 3/3
36.4
4 3/3 33.9 3/3 35.9 3/3 31.9 3/3
37.1
3/3 33.9 3/3 36.2 3/3 31.5 3/3 36.7
6 3/3 33.4 3/3 36.0 3/3 31.4 3/3
36.4
7 3/3 33.8 3/3 35.7 3/3 31.7 3/3
36.5
8 3/3 33.2 3/3 34.9 3/3 31.8 3/3
36.3
9 3/3 34.2 3/3 36.3 3/3 32.1 3/3
36.7
3/3 34.1 3/3 36.1 3/3 31.9 3/3 36.6
11 3/3 33.9 3/3 36.0 3/3 31.7 3/3
36.8
12 3/3 34.1 3/3 36.3 3/3 31.9 3/3
36.9
13 3/3 33.8 3/3 36.1 3/3 31.7 3/3
37.1
14 3/3 34.2 3/3 36.3 3/3 31.3 3/3
36.8
3/3 33.7 3/3 35.7 3/3 30.9 3/3 36.5
[00212] Table 8.1. Interference Data (EIEC)
Panel Salmonella Campylobacter Shigella STEC
Reactivity Avg Ct Reactivity Avg Ct Reactivity Avg Ct Reactivity Avg Ct
Control 3/3 33.6 3/3 35.9 3/3 31.3 3/3
36.5
A 3/3 33.7 3/3 36.0 3/3 20.7 3/3
37.3
B 3/3 33.7 3/3 35.9 3/3 20.4 3/3
38.0
[00213] The primers and probes did not react with any of the challenge
organisms listed in
Table 6, as shown in Table 7. Moreover, the primers and probes showed 100 /0
positivity
when target bacteria were present in a reaction well, as shown in Table 8.
Thus, these
primers and probes demonstrate no cross-reactivity with organisms that are
commonly
found in stool or cause similar disease states as the target organisms. The
primers and probes
demonstrated high specificity, even while in the presence of commonly found
non-target
organisms.
[00214] Additionally, since Shigella and EIEC have substantially identical
ipaH genes, the
Shigella primers and probes reacted with the organisms in Table 6.1, as shown
in Table 7.1.
And the primers and probes also showed 100 /0 positivity when target bacteria
were present
in a reaction well, as shown in Table 8.1. As such, the Shigella primers and
probes may be
used to detect the presence of EIEC in a sample.
73
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
Example 5 ¨ Shigella Primer and Probe Screening
[00215] Several primer and probe combinations were prepared and tested for
amplification
and detection of Shigella sonnei. Combinations are described in Table 9 below.
These
primer-probe combinations were tested against three concentrations of a
serially diluted
stock concentration of Shigella sonnei. Dilutions were made into a sample
transport reagent
and the 500 CFU/mL, 150 CFU/mL, and 50 CFU/mL concentrations were tested.
Negative
reaction wells were sample transport media. Reaction conditions were set up in
triplicate and
real-time amplification and detection reactions were performed. RFU and Ct
results were
analyzed and are presented below.
74
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[00216] Table 9. Primer & Probe Combinations
Primer-Probe
SEQ ID NO: Oligo Type Modifications & Labels*
Combo No.
Forward
SEQ ID NO:34 Primer
Reverse
Combo 1.1 SEQ ID NO:22 . 5mC at residues 5 and 16
Primer
Taqman 5mC at residues 5, 11, and 12
SEQ ID NO:46
Probe ROX/BHQ2
Forward
SEQ ID NO:34 .
Primer
Reverse
Combo 1.2 SEQ ID NO:22 . 5mC at residues 5 and 16
Primer
Taqman
SEQ ID NO:29 ROX/BHQ2
Probe
Forward 5mC at residues 7 and 15
SEQ ID NO:15 .
Primer Inosine at residue 3
Reverse
Combo 2 SEQ ID NO:17 .
Primer
Taqman ROX/BHQ2
SEQ ID NO:16
Probe Inosine at residue 16
5mC at residues 5, 11, 12 and
Forward
SEQ ID NO:32 . 15
Primer
Inosine at residue 9
Combo 3 Reverse
SEQ ID NO:33 .
Primer
Taqman
SEQ ID NO:24 ROX/BHQ2
Probe
* 5mC refers to a residue that comprises 5-methylcytosine. BHQ refers to Black
Hole
Quencher. FAM refers to fluorescein. ROX refers to carboxyrhodamine.
[00217] Results showed 100% positivity for each primer-probe combination (Ct
threshold
set at 1,000 RFU). Primer-probe combination 2 showed the highest RFU
(approximately
12,000 RFU at 500 cfu/mL), though at 50 cfu/mL one of the replicates fell to
about 2,000
RFU while the other two replicates were at about 8,000 RFU. Primer-probe
combination 1.2
showed good overall results with consistent RFU and Ct values for the tested
replicate
conditions. RFU and Ct results are shown in Table 10.
CA 03226812 2024-01-15
WO 2023/010008
PCT/US2022/074151
[00218] Table 10. Combination Screening
Individual
Primer-Probe
Condition RFU Average
Average Ct
Combo No. RFU
measurements
128.47
STM only 138.43 137
144.71
2938.8
S. sonnet
2528.24 2,279 40.87
50 CFU/mL
1370.21
Combo 1.1
3348.32
S. sonnet
3961.5 3,546 38.88
150 CFU/mL
3327.68
4401.85
S. sonnet
5090.91 4,346 37.81
500 CFU/mL
3544.61
79.32
STM only 81.6 88
103
4144.9
S. sonnet
6076.92 4,856 38.98
50 CFU/mL
4345
Combo 1.2
5442.56
S. sonnet
7344 6,492 37.18
150 CFU/mL
6690.76
5658.92
S. sonnet
7793.4 6,759 36.51
500 CFU/mL
6826.04
150.8
STM only 115.7 122
100.28
2127.4
S. sonnet
8369.19 6,090 38.88
50 CFU/mL
7773.1
Combo 2
9423
S. sonnet
9812.83 9,633 37.15
150 CFU/mL
9663.4
11020.7
S. sonnet
11591.6 11,469 35.31
500 CFU/mL
11794.2
111
Combo 3 STM only 116.4 109
99.28
76
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
= 3604
S. sonnet
5927.2 5,108 39.91
50 CFU/mL
5792.7
= 7257.6
S. sonnet
6773 7,436 37.66
150 CFU/mL
8276
= 6957.8
S. sonnet
7275.8 7,304 36.87
500 CFU/mL
7680.6
Example 6 ¨ Co-Infection/Competitive Interference
[00219] The performance of detecting two or more target organisms in a single
sample,
using the primer-probe combination shown in Table 1 in a multiplex PCR assay,
was
measured. To create the co-infected sample, a negative Cary-Blair stool matrix
was spiked
with a combination of a high concentration (1E6 CFU/mL) and a low
concentration
(3xLoD) of target organisms, as illustrated in Table 11. The primer-probe
combination was
tested against a target organism at the low concentration in the absence of a
co-infectant,
and was further tested with a combination of a target organism at the low
concentration and
a separate target organism at the high concentration (see Table 12).
[00220] Table 11. Target Bacteria and Representative Strain Used.
Target Organism Representative Strain
Salmonella enterica CDC 6516-60
Campylobacter coli CIP 7080
Shigella sonnei AMC 43-GG9
STEC-0157 0157:H7
[00221] Table 12. Results of GI-Bac1 Co-Infection
High Salmonella Campylobacter STEC
Low
Conc. Mean Mean Mean
Mean
Conc.
1E6 React. Ct React. Ct React. Ct React. Ct
3X LoD
CFU/mL (SD) (SD) (SD) (SD)
33.93
None 3/3 0/3 0/3 0/3
(0.7)
33.17 24.05
Salmonella C. coli 3 / 3 3 / 3 0/3 0/3
33.29 20.47
Shigella 3/3 0/3 3/3 0/3
(0.1) (0.2)
77
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
33.23
23.40
STEC 3/3 0/3 - 0/3 - 3/3
(0.2)
(0.1)
35.37
None 0/3 - 3/3 (0.2) 0/3 - 0/3
22.09 35.58
Salmonella 3/3 3/3 0/3 - 0/3
C. co/i (0.06) (0.2)
35.56 20.50
Shigella 0/3 - 3/3 3/3 0/3
(0.2) (0.2)
35.06
23.19
STEC 0/3 - 3/3 0/3 - 3/3
(0.2)
(0.1)
32.16
None 0/3 - 0/3 - 3/3 0/3
(0.0)
22.38 32.09
Salmonella 3/3 0/3 - 3/3 0/3
(0.2) (0.2)
Shigella
24.54 32.57
C. coli 0/3 - 3/3 3 / 3 0/3
(0.2) (0.3)
31.69
23.32
STEC 0/3 - 0/3 - 3/3 3/3
(0.2)
(0.2)
35.80
None 0/3 - 0/3 - 0/3 - 3/3
(0.3)
22.51
36.04
Salmonella 3/3 0/3 - 0/3 - 3/3
STEC- (0.2) (0.3)
0157 24.22 36.21
C. coli 0/3 - 3/3 0 / 3 - 3/3
(0.3)
(0.6)
20.52
36.57
Shigella 0/3 - 0/3 - 3/3 3 / 3
(0.06)
(0.2)
[00222] Detection of both the high and low concentrations of all target
bacteria were 100%.
There were no false positives, and no competitive interference was observed.
The data show
that the primer-probe combination can accurately detect multiple target
bacteria present in a
single sample using multiplex PCR.
Example 7 - Mitigating Inhibition of Amplication Reactions with a-Cyclodextrin
and/or Polysorbate 20
[00223] Detergents that are present in, e.g., wash buffers, are known to
inhibit or diminish
nucleic acid amplification reactions. To investigate the ability of a-
cyclodextrin and
polysorbate 20 to mitigate such negative/inhibitory effects, several PCR
reaction mixtures
were prepared for testing with samples containing a detergent.
78
CA 03226812 2024-01-15
WO 2023/010008 PCT/US2022/074151
[00224] An master mix was prepared to contain DNA polymerase at 0.46 U/pLL,
reverse
transcriptase at 0.5 U/pLL, RNase inhibitor at 0.2 U/pLL, dNTPs at 0.25 mM
each, dUTP at
0.05 mM, inorganic salts including KC1 and MgCl2 at 81 and 5.1 mM, EDTA at 0.1
mM, and
primers and probes for amplification and detection of a target nucleic acid.
The master mix
was separated into conditions (A) through (F), wherein conditions (B) and (D)
further
contained polysorbate 20 at 0.025% (v/v), conditions (B), (C) and (F) further
contained 12.5
mg/mL a-cyclodextrin, condition (C) further contained polysorbate 20 at 0.13%
(v/v), and
condition (E) further contained 50 mg/mL a-cyclodextrin. Samples were prepared
by
spiking the target nucleic acid into a suitable media and were incubated in a
buffered reagent
containing poly-T coated magnetic microparticles and a target capture oligomer
to bind the
target nucleic acids to a magnetic solid support. The magnetic microparticles
and bound
nucleic acid were separated out, and following additional separation and
washing, an eluate
containing nucleic acid was recovered. The eluate was divided into separate
containers, and
one of the eluate portions was further spiked with 30% (v/v) of wash buffer to
produce
eluates containing 100 mg/mL of sodium dodecyl sulfate to simulate carry over
of wash
buffer from an upstream sample processing step. Each of the above master mix
conditions
(A) to (F) were combined with an aliquot of the wash-buffer-spiked or non-
spiked eluate (20
1_,LL master mix, 10 1_,LL eluate, 30 1_,LL total reaction volume per
replicate). Thus, the final
concentration of polysorbate 20 and/or a-cyclodextrin in each reaction mixture
was 2/3 of
the concentration listed above for the master mix. Real-time amplification and
detection
reactions were set up for the replicates, and the reactions were performed
using a thermal
cycling instrument (Panther Fusion Instrument, Hologic, Inc., San Diego, CA).
Results are
presented in Table 13 below.
[00225] Table 13. Amplification Results
Master Wash
Average SD
Mix Buffer Average Ct SD Ct
Positives RFU RFU
Condition Spike
(A) No 20/20 33.2 0.8 22225 3134
(A) Yes 1/20 38.2* n/a 791 n/a
79
CA 03226812 2024-01-15
WO 2023/010008
PCT/US2022/074151
Master Wash
N Average SD
Mix Buffer Average Ct SD Ct
Positives RFU RFU
Condition Spike
(B) No 20/20 32.2 0.5 25043 2460
(B) Yes 20/20 32.5 0.9 24276
2879
(C) No 20/20 32.4 0.5 22664
3118
(C) Yes 20/20 32.3 0.5 23200 2561
P) Yes 20/20 34.2 0.6 15690 1785
(E) Yes 19/19 34.2 0.8 19965
2826
(F) Yes 20/20 35.2 1.2 19346
3674
*Ct value is for a single replicate, not an average
[00226] The addition of a-cyclodextrin and polysorbate 20 into the reaction
mixture
mitigated the negative/inhibitory effects that detergents have on the nucleic
acid
amplification reactions. The Ct and RFU values further indicate that the
combination of
these two reagents had a synergistic mitigating effect on the detergent-
induced inhibition
relative to the mitigating effects observed using either a-cyclodextrin or
polysorbate 20
alone.
[00227] Table of Sequences.
SEQ ID Oligo
Sequence
Description
NO: ID (N =
inosine)
E. co/i Set1-stx1-
1 349336 CTATACCACGTTACAGCGTGTTGCAG
Probe2
E. co/i Set1-stx1-
2 349337 TTATCTGCATCCCCGTACGACTGATC
Probe3
E. co/i Set1-stx1-
3 349794 GAAGTAGTCAACGAATGGCG
RP2
E. co/i Set1-stx2-
4 349795 CCATGACAACGGACAGCAGTTATA
FP2
E. co/i Set1-stx2-
349340 ACTCTGCAACGTGTCGCAGCGCT
Probe4
E. co/i Set1-stx2-
cio 6 349723 AACGTTCCGGAATGCAAATCAGTCGTC
Probe7
1,9
7 E. co/i Set1-stx2-RP 348780 CGCCAGATATGATGAAACCAGTGAG
8 C. co/i Set1-cadF-FP 348752 GAGCGTGGCTTATCTTGACC
C. co/i Set1-cadF-
9 349690 ACTGTCTGGATACGACTTTTATCTACACCG
Probe7
C. co/i Set1-cadF-RP 348754 CAGAAAGACGCGCTAACAGCGT
C. jejuni S et1-glyA-
11 349910 GCTAATGTTCAGCCTAATTCAGGT
FP3
Salmonella Setl-
12 348725 GAACGTGTTTCCGTGCGTAAT
InvA-FP
Salmonella Set1-
0
349688
InvA-Probe6
13 ATGGAAGCGCTCGCATTGTGGGC
Salmonella Set1-
348726
InvA-Probe
Salmonella Set1-
14 349577 ATATAACGCGCCATTGCYCCACGAATATG
InvA-RP3
Shigella Set2-ipaI-I-
15 348762 AGNGTACTCATTCTCCAGCATCTC
FP
Shigella Set2-ipaI-I-
cie 349863 TTCTGCTCTTCTGCCNGCGCCCA
Probe
r,
16
0"
Shigella Set2-ipaI-I-
348764 TTCTGCTCTTCTGCCNGCGCCCA
Probe
Shigella Set2-ipaI-I-
17 348765 TACGGACTGGTTCTCCCTCT
RP
C. jejuni Set1-glyA-
349913
Probe9
18 CTCAAGCYAATCAAGGTGTTTATGCGGCT
C. jejuni Set1-glyA- 350333
Probe9
C. jiinni Set1-glyA-
19 349793 CCATGACTTAAATCCATTCCTANAA
RP2
E. coli Setl-stxl-
20 349626 GGTTACATTGTCTGGTGACAGTAG
FP2
Salmonella Set1-
21 348715 AAGAGATGAATGCNTTCAAAGANCC
0 rgC-FP
Shigella Set1-ipaI-1-
0
22 348761 AATGCGTTTCTATGGCGTGTCGG
t..)
RP
2
-::--,
Salmonella Set2-
23 348729 ACTGCTCGTAATTCNCCGCCATTGGC
o
InvA-Probe
cio'
Shigella Set3-ipaI-I-
24 348767 AGGGAGAGCAGAGCGCCGGTATCAT
Probe
Salmonella Set2-
25 349092 TGAANGCNCAGTCACAAATG
0 rgC-Prob e3
Salmonella Set2-
P
26 348721 CAGGANGTCATTTGTGACTGTGCG
0 rgC-Prob e2
2
IV"
00'
cle
W Salmonella Set3-
r,
27 348733 CAGTGCGATCAGGAAATCAACCAGA
0"
InvA-RP
.^.'
Salmonella Set1-
,
28 348727 CCACGAATATGCTCCACNAGGTTAATG
InvA-RP
Shigella Set1 -ipaI-I-
29 348760 CCAGAGGGAGAACCAGTCCG
Probe2
Salmonella Set3-
30 348723 CCTCATATAAATGNGTGCCCGGNTC
0 rgC-Prob e
.o
n
Salmonella Set2-
31 348730 CGGATCCCTTTGCGAATAANATCCTCA
InvA-RP
cp
t..)
o
t..)
Shigella Set3-ipaI-I-
t..)
-::--,
32 348766 CGGGCAATNTCCTCCAGAATTT -4
FP
Shigella Set3-ipaI-I-
33 348768 CTCCTGGTCCATCAGGCATC
RP
Shigella Set1-ipaI-I-
0
34 348758 CTTCCGTACGCTTCAGTACAG
t..)
FP
=
t..)
Salmonella Set3-
-::--,
35 348722 GCAGCAAACGGCTATGCTACAA
.
OrgC-FP
g
o
cio
Salmonella Set2-
36 348719 GCCCGANAAAATAATCTCCTGCATC
OrgC-RP
C. co/i Set1-cadF-
348753
Probe
C. co/i Set1-cadF-
37 349433 CGGTGTAGATANAAGTCGTATCCAGACAG
Probe3
P
C. co/i Set1-cadF-
.
349435
"w
Probe5
ig
.3
cio
4,. Salmonella Set2-
r,
38 348718 GGGCACCCATTTATATGAGGCNTTA
IV
OrgC-FP
"0
,
C. co/i Set1-cadF-
,
39 349432 TCTGGATACGACTTNTATCTACACCG
Probe2
Salmonella Set3-
40 348724 GGTCATTTGTGACTGNGCNTTCA
OrgC-RP
Salmonella Set3-
41 348731 GTGCTCGTTTACGACCTGAATTACTG
InvA-FP
.d
Salmonella Set2-
n
42 348728 TCGTGGAGCNATGGCNCGTTATAT
InvA-FP
cp
t..)
o
t..)
Salmonella Set3-
t..)
43 348732 TCTATGTTCGTCATNCCATTACCTACC
-::--,
-4
InvA-Probe
u,
Salmonella Set2-
44 348720 TGAANGCNCAGTCACAAATGAC
OrgC-Probe1
0
t..)
o
t..)
Salmonella Set1-
c,.)
45 348716 TGCTGCTCANAAGANACANAAGC
-::--,
OrgC-Probe
.
=
o
o
cio
Shigella Set1-ipal-I-
46 348759 TGGTCAGAAGCCGTGAAGAGAATG
Probe1
Salmonella Set1-
47 348717 TGTNTTGTAGCATAGCCGTT
OrgC-RP
E. co/i Set1-stx1-
48 348770 ACAGCGTGTTGCAGGGATCAGTCGT
Probe
P
49 E. co/i Set1-stx1-FP 348769 CGGTTACATTGTCTGGTGACAGTAG
2
N,"
.3'
cio
u,
r,
IV
IV0
1
I
.o
n
,-i
cp
t..)
=
t..)
t..)
-::--,
-4
4,.
u,
